Package ‘curatedCRCData’

February 1, 2017

Type Package
Title Colorectal Cancer Gene Expression Analysis
Version 2.6.0
Date 2015-07-09
Author Princy Parsana, Markus Riester, Curtis Huttenhower, Levi Waldron
Maintainer Princy Parsana <princy parsana@jhu.edu>
Description The curatedCRC package provides relevant functions and data for gene expression analysis in patients with colorectal cancer.
Depends R (>= 2.10.0), nlme
Imports BiocGenerics
Suggests survival, RUnit, metafor, genefilter, logging, sva, xtable, futile.logger, BiocStyle
Requires affy
License Artistic-2.0
Namespace auto
biocViews Colorectal, Cancer, TCGA, ExperimentData, RNAExpressionData
URL https://bitbucket.org/biobakery/curatedcrcdata
NeedsCompilation no

R topics documented:

curatedCRCData-package .................................................. 2
GSE11237_eset ............................................................. 3
GSE12225/GPL3676_eset .................................................. 5
GSE12945_eset ............................................................. 8
GSE13067_eset ............................................................. 11
GSE13294_eset ............................................................. 13
GSE14095_eset ............................................................. 15
GSE14333_eset ............................................................. 17
GSE16125/GPL5175_eset .................................................. 20
GSE17536_eset ............................................................. 23
GSE17537_eset ............................................................. 26
GSE17538/GPL570_eset .................................................. 29
GSE18105_eset ............................................................. 33
curatedCRCData-package

Clinically Annotated Data for the CRC Cancer Transcriptome

Description

The curatedCRCData package provides manually curated clinical data, uniformly processed expression data, and convenience functions for gene expression analysis in patients with colorectal cancer.

Note: For staging, the "summarystage" was curated as using information on the pathologic T, N, and M stages, such that "early" = T stage of Tis through T3 and N0 and M0 and "late" = T stage of 4 and/or any N>0 or M>0.

Details

- Package: curatedCRCData
- Type: Package
- Version: 2.6.0
- Date: 2015-07-09
- License: Artistic-2.0
- Depends: R (>= 2.10.0), affy
Author(s)
Princy Parsana, Markus Riester, Levi Waldron
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health
Maintainer: Princy Parsana <princyparsana@jhu.edu>

Examples
## List all datasets:
data(package="curatedCRCData")
##

GSE11237_eset  

Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation.

Description
Cancer cells treated with the cyclooxygenase-2 inhibitor celecoxib show growth inhibition and induced apoptosis. This study was conducted to determine if the same processes are relevant to celecoxib’s effects on human colorectal adenocarcinomas treated in vivo. A cohort of 23 patients with primary colorectal adenocarcinomas was randomised to receive a 7-d course of celecoxib (400mg b.i.d.) or no drug prior to surgical resection. Gene expression profiling was performed on resected adenocarcinomas from the cohort of patients. Using fold change (>1.5) and p-value (<0.05) cut-offs, 190 genes were differentially expressed between adenocarcinomas from patients receiving celecoxib and those that did not. The celecoxib pre-treated samples showed decreased expression levels in multiple genes involved in cellular lipid and glutathione metabolism; changes associated with diminished cellular proliferation. Celecoxib pre-treatment for 7 d in vivo is associated with alterations in colorectal adenocarcinoma gene expression which are suggestive of diminished cellular proliferation.

Usage
data( GSE11237_eset )

Format
experimentData(eset):
Experiment data
Experimenter name: Auman JT, Church R, Lee SY, Watson MA, Fleshman JW, McLeod HL. Celecoxib pre-
Laboratory: Auman, Mcleod 2008
Contact information:
Title: Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene
URL:
PMIDs: 18653328

Abstract: A 147 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
  Affymetrix Human Genome U95 Version 2 Array
platform_shorttitle:
  Affymetrix HG_U95Av2
platform_summary:
  hgu95av2
platform_manufacturer:
  Affymetrix
platform_distribution:
  commercial
platform_accession:
  GPL8300
platform_technology:
  in situ oligonucleotide
warnings:
  No warnings yet

Preprocessing: rma
featureData(eset):
  An object of class 'AnnotatedDataFrame'
  featureNames: AADAC AAK1 ... ZZZ3 (8933 total)
  varLabels: probeset gene
  varMetadata: labelDescription

Details

assayData: 8933 features, 23 samples
Platform type: hgu95av2

Available sample meta-data:

alt_sample_name:
  Length  Class  Mode
  23  character  character

sample_type:
tumor
  23

summarygrade:
  high  low
  4  19

G:
  1  2  3
  3 16  4

summarystage:
  early  late
  12  11
Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis.
Accurate staging of rectal tumors is essential for making the correct treatment choice. In a previous study, we found that loss of 17p, 18q and gain of 8q, 13q and 20q could distinguish adenoma from carcinoma tissue and that gain of 1q was related to lymph node metastasis. In order to find markers for tumor staging, we searched for candidate genes on these specific chromosomes. We performed gene expression microarray analysis on 79 rectal tumors and integrated these data with genomic data from the same sample series. We performed supervised analysis to find candidate genes on affected chromosomes and validated the results with qRT-PCR and immunohistochemistry. Integration of gene expression and chromosomal instability data revealed similarity between these two data types. Supervised analysis identified up-regulation of EFNA1 in cases with 1q gain, and EFNA1 expression was correlated with the expression of a target gene (VEGF). The BOP1 gene, involved in ribosome biogenesis and related to chromosomal instability, was over-expressed in cases with 8q gain. SMAD2 was the most down-regulated gene on 18q, and on 20q, STMN3 and TGIF2 were highly up-regulated. Immunohistochemistry for SMAD4 correlated with SMAD2 gene expression and 18q loss. On basis of integrative analysis this study identified one well known CRC gene (SMAD2) and several other genes (EFNA1, BOP1, TGIF2 and STMN3) that possibly could be used for rectal cancer characterization.

Usage
data( GSE12225.GPL3676_eset )

Format
experimentData(eset):
  Experiment data
  Laboratory: Lips, Morreau 2008
  Contact information:
    Title: Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis.
    URL: 
    PMIDs: 18959792

  Abstract: A 221 word abstract is available. Use 'abstract' method.
  Information is available on: preprocessing
  notes:
  platform_title:
    NKI-CMF Homo sapiens 35k oligo array
  platform_shorttitle:
    NA
  platform_summary:
    nk1-cmf homo sapiens 35k oligo array
  platform_manufacturer:
    Central Microarray Facility, NKI Amsterdam
  platform_distribution:
    non-commercial
  platform_accession:
    GPL3676
  platform_technology:
    spotted oligonucleotide
  warnings:
    No warnings yet
Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
  featureNames: 15E1.2///TRIAP1///SFRS9///DYNNL1///COX6A1
  1810006K21Rik///C11orf10 ... ZZZ3 (17015 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 17015 features, 42 samples
Platform type: nki-cmf homo sapiens 35k oligo array
---------------------------
Available sample meta-data:
---------------------------

alt_sample_name:
    Length  Class  Mode
    42 character character

sample_type:
tumor
42

primarysite:
re
42

summarystage:
early  late
30  12

T:
  1  2  3
  14 27  1

N:
  0  1  2
  30  6  6

M:
  0
42

location:
rectum
42

summarylocation:
1
42
Wiskott-Aldrich syndrome (WAS) predisposes patients to leukemia and lymphoma. WAS is caused by mutations in the protein WASP which impair its interaction with the WIPF1 protein. Here, we aim to identify a module of WIPF1-coexpressed genes and to assess its use as a prognostic signature for colorectal cancer, glioma, and breast cancer patients. Two public colorectal cancer microarray data sets were used for discovery and validation of the WIPF1 co-expression module. Based on expression of the WIPF1 signature, we classified more than 400 additional tumors with microarray data from our own experiments or from publicly available data sets according to their WIPF1 signature expression. This allowed us to separate patient populations for colorectal cancers, breast cancers, and gliomas for which clinical characteristics like survival times and times to relapse were analyzed. Groups of colorectal cancer, breast cancer, and glioma patients with low expression of the WIPF1 co-expression module generally had a favorable prognosis. In addition, the majority of WIPF1 signature genes are individually correlated with disease outcome in different studies. Literature gene network analysis revealed that among WIPF1 co-expressed genes known direct transcriptional targets of c-myc, ESR1 and p53 are enriched. The mean expression profile of WIPF1 signature genes is correlated with the profile of a proliferation signature. The WIPF1 signature is the first microarray-based prognostic expression signature primarily developed for colorectal cancer that is instrumental in other tumor types: low expression of the WIPF1 module is associated with better prognosis.

Usage

data( GSE12945_eset )

Format

experimentData(eset):
Experimenter name: Staub E, Groene J, Heinze M, Mennerich D et al.??An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types.
Laboratory: Staub, Rosenthal 2009
Contact information:
Title: An expression module of WIPF1-coexpressed genes identifies patients with favorable progno
Abstract: A 241 word abstract is available. Use 'abstract' method.

Information is available on: preprocessing

Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1CF A2M ... ZZZ3 (12986 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 12986 features, 62 samples
Platform type: hgu133a
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)

records n.max n.start events median 0.95LCL 0.95UCL
62 62 62 12 NA NA NA

---------------------------
Available sample meta-data:
---------------------------

alt_sample_name:
Length Class Mode
62 character character

sample_type:
tumor
62
primarysite:
core 29 33

summarygrade:
high low 31 31

G:
2 3
31 31

summarystage:
early late 36 26

T:
2 3 4
16 42 4

N:
0 1 2
36 14 12

M:
0 1 X
56 5 1

age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
38.00 59.00 65.00 64.45 73.75 87.00

recurrence_status:
norecurrence recurrence NA's
47 8 7

days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
210 1005 1395 1267 1620 1920

vital_status:
deceased living 12 50

location:
Length Class Mode
62 character character

summarylocation:
1  r NA's
48 13 1
About 15% of colorectal cancers harbor microsatellite instability (MSI). MSI-associated gene expression changes have been identified in colorectal cancers, but little overlap exists between signatures hindering an assessment of overall consistency. Little is known about the causes and downstream effects of differential gene expression. DNA microarray data on 89 MSI and 140 microsatellite-stable (MSS) colorectal cancers from this study and 58 MSI and 77 MSS cases from three published reports were randomly divided into test and training sets. MSI-associated gene expression changes were assessed for cross-study consistency using training samples and validated as MSI classifier using test samples. Differences in biological pathways were identified by functional category analysis. Causation of differential gene expression was investigated by comparison to DNA copy-number data. MSI-associated gene expression changes in colorectal cancers were found to be highly consistent across multiple studies of primary tumors and cancer cell lines from patients of different ethnicities (P < 0.001). Clustering based on consistent changes separated additional test cases by
MSI status, and classification of individual samples predicted MSI status with a sensitivity of 96% and specificity of 85%. Genes associated with immune response were up-regulated in MSI cancers, whereas genes associated with cell-cell adhesion, ion binding, and regulation of metabolism were down-regulated. Differential gene expression was shown to reflect systematic differences in DNA copy-number aberrations between MSI and MSS tumors (P < 0.001). Our results show cross-study consistency of MSI-associated gene expression changes in colorectal cancers. DNA copy-number alterations partly cause the differences in gene expression between MSI and MSS cancers.

Usage

data( GSE13067_eset )

Format

experimentData(eset):
  Experiment data
  Experimenter name: Jorissen RN, Lipton L, Gibbs P, Chapman M et al. DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers.  
  Laboratory: Jorissen and Sieber 2008
  Contact information:
  Title: DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers.
  URL: 
  PMIDs: 19088021

  Abstract: A 251 word abstract is available. Use 'abstract' method.
  Information is available on: preprocessing
  notes:
  platform_title:
    [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
  platform_shorttitle:
    Affymetrix HG-U133Plus2
  platform_summary:
    hgu133plus2
  platform_manufacturer:
    Affymetrix
  platform_distribution:
    commercial
  platform_accession:
    GPL570
  platform_technology:
    in situ oligonucleotide
  warnings:
    No warnings yet

Preprocessing: frma
featureData(eset):
  An object of class 'AnnotatedDataFrame'
  featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
  varLabels: probeset gene
  varMetadata: labelDescription
Details

assayData: 19320 features, 74 samples
Platform type: hgu133plus2
-----------------------------
Available sample meta-data:
-----------------------------

alt_sample_name:
    Length Class Mode
    74 character character

sample_type:
tumor
    74

msi:
MSI MSS
   11 63

batch:
    Length Class Mode
    74 character character

uncurated_author_metadata:
    Length Class Mode
    74 character character

GSE13294_eset DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers.

Description

About 15% of colorectal cancers harbor microsatellite instability (MSI). MSI-associated gene expression changes have been identified in colorectal cancers, but little overlap exists between signatures hindering an assessment of overall consistency. Little is known about the causes and downstream effects of differential gene expression. DNA microarray data on 89 MSI and 140 microsatellite-stable (MSS) colorectal cancers from this study and 58 MSI and 77 MSS cases from three published reports were randomly divided into test and training sets. MSI-associated gene expression changes were assessed for cross-study consistency using training samples and validated as MSI classifier using test samples. Differences in biological pathways were identified by functional category analysis. Causation of differential gene expression was investigated by comparison to DNA copy-number data. MSI-associated gene expression changes in colorectal cancers were found to be highly consistent across multiple studies of primary tumors and cancer cell lines from patients of different ethnicities (P < 0.001). Clustering based on consistent changes separated additional test cases by MSI status, and classification of individual samples predicted MSI status with a sensitivity of 96% and specificity of 85%. Genes associated with immune response were up-regulated in MSI cancers, whereas genes associated with cell-cell adhesion, ion binding, and regulation of metabolism were down-regulated. Differential gene expression was shown to reflect systematic differences in DNA
copy-number aberrations between MSI and MSS tumors (P < 0.001). Our results show cross-study consistency of MSI-associated gene expression changes in colorectal cancers. DNA copy-number alterations partly cause the differences in gene expression between MSI and MSS cancers.

Usage
data( GSE13294_eset )

Format
experimentData(eset):
Experiment data
  Laboratory: Jorissen and Sieber 2008
  Contact information:
    Title: DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers.
    URL: 
    PMID: 19088021
  Abstract: A 251 word abstract is available. Use 'abstract' method.
  Information is available on: preprocessing
  notes:
  platform_title:
    [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
  platform_shorttitle:
    Affymetrix HG-U133Plus2
  platform_summary:
    hgu133plus2
  platform_manufacturer:
    Affymetrix
  platform_distribution:
    commercial
  platform_accession:
    GPL570
  platform_technology:
    in situ oligonucleotide
  warnings:
    No warnings yet
  Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
  featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
  varLabels: probeset gene
  varMetadata: labelDescription

Details
assayData: 19320 features, 155 samples
Platform type: hgu133plus2
----------
Available sample meta-data:
**Description**

FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients. However, about half of all patients show resistance to this regimen and some develop adverse symptoms such as neurotoxicity. In order to select patients who would benefit most from this therapy, we aimed to build a predictor for the response to FOLFOX using microarray gene expression profiles of primary CRC samples. Forty patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received modified FOLFOX6. Responders and nonresponders were determined according to the best observed response at the end of the first-line treatment. Gene-expression profiles of primary CRC were determined using Human Genome GeneChip arrays U133. We identified discriminating genes whose expression differed significantly between responders and nonresponders and then carried out supervised class prediction using the k-nearest-neighbour method. We identified 27 probes that were differentially expressed between responders and nonresponders at significant levels. Based on the expression of these genes, we constructed a FOLFOX response predictor with an overall accuracy of 92.5%. The sensitivity, specificity, positive and negative predictive values were 78.6%, 100%, 100% and 89.7%, respectively. The present model suggests the possibility of selecting patients who would benefit from FOLFOX therapy both in the metastatic and the adjuvant setting. To our knowledge, this is the first study to establish a prediction model for the response to FOLFOX chemotherapy based on gene expression by microarray analysis.

**Usage**

data( GSE14095_eset )
experimentData(eset):
Experiment data
Experimenter name: Watanabe T, Kobunai T, Yamamoto Y, Matsuda K et al.
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
Laboratory: Watanabe, Hashimoto 2008
Contact information:
Title: Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
URL:
PMIDs: 21680303

Abstract: A 241 word abstract is available. Use ‘abstract’ method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
Affymetrix HG-U133Plus2
platform_summary:
hgu133plus2
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL570
platform_technology:
in situ oligonucleotide
warnings:
No warnings yet

Preprocessing: default
featureData(eset):
An object of class ‘AnnotatedDataFrame’
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 19320 features, 189 samples
Platform type: hgu133plus2
-----------------------------------------------
Available sample meta-data:
-----------------------------------------------

alt_sample_name:
Length Class Mode
189 character character

sample_type:
tumor
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer.

PURPOSE: Colorectal cancer prognosis is currently predicted from pathologic staging, providing limited discrimination for Dukes stage B and C disease. Additional markers for outcome are required to help guide therapy selection for individual patients. EXPERIMENTAL DESIGN: A multisite single-platform microarray study was done on 553 colorectal cancers. Gene expression changes were identified between stage A and D tumors (three training sets) and assessed as a prognosis signature in stage B and C tumors (independent test and external validation sets). RESULTS: One hundred twenty-eight genes showed reproducible expression changes between three sets of stage A and D cancers. Using consistent genes, stage B and C cancers clustered into two groups resembling early-stage and metastatic tumors. A Prediction Analysis of Microarray algorithm was developed to classify individual intermediate-stage cancers into stage A-like/good prognosis or stage D-like/poor prognosis types. For stage B patients, the treatment adjusted hazard ratio for 6-year recurrence in individuals with stage D-like cancers was 10.3 (95% confidence interval, 1.3-80.0; P = 0.011). For stage C patients, the adjusted hazard ratio was 2.9 (95% confidence interval, 1.1-7.6; P = 0.016). Similar results were obtained for an external set of stage B and C patients. The prognosis signature was enriched for downregulated immune response genes and upregulated cell signaling and extracellular matrix genes. Accordingly, sparse tumor infiltration with mononuclear chronic inflammatory cells was associated with poor outcome in independent patients. CONCLUSIONS: Metastasis-associated gene expression changes can be used to refine traditional outcome prediction, providing a rational approach for tailoring treatments to subsets of patients. (Clin Cancer Res 2009;15(24):7642-51).

Usage
data(GSE14333_eset)

Format
eperimentData(eset):
Experiment data
Experimenter name: Jorissen RN, Gibbs P, Christie M, Prakash S et al.
Laboratory: Jorissen and Sieber 2008
Contact information:
Title: Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer.
URL:
PMIDs: 19996206

Abstract: A 257 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
  platform_title:
    [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
  platform_shorttitle:
    Affymetrix HG-U133Plus2
  platform_summary:
    hgu133plus2
  platform_manufacturer:
    Affymetrix
  platform_distribution:
    commercial
  platform_accession:
    GPL570
  platform_technology:
    in situ oligonucleotide
warnings:
  No warnings yet

Preprocessing: frma
featureData(eset):
  An object of class 'AnnotatedDataFrame'
  featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
  varLabels: probeset gene
  varMetadata: labelDescription

Details

  assayData: 19320 features, 290 samples
  Platform type: hgu133plus2
  ---------------------------
  Available sample meta-data:
  ---------------------------

  alt_sample_name:
    Length Class Mode
    290 character character

  sample_type:
    tumor
    290

  primarysite:
    core NA's
    250 39 1

  summarystage:
    early late NA's
    44 152 94
N:
|    | 0  NA's | 138 152 |

M:
|    | 0  1 | 229 61 |

Dstage:
| A | B | C | D | 44 94 91 61 |

age_at_initial_pathologic_diagnosis:
<table>
<thead>
<tr>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
</tr>
</thead>
<tbody>
<tr>
<td>26.00</td>
<td>58.00</td>
<td>67.00</td>
<td>65.96</td>
<td>75.00</td>
<td>92.00</td>
</tr>
</tbody>
</table>

summarylocation:
<table>
<thead>
<tr>
<th>l</th>
<th>r</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>161</td>
<td>125</td>
<td>4</td>
</tr>
</tbody>
</table>

gender:
| f  | m  |
| 126 | 164 |

stageall:
<table>
<thead>
<tr>
<th>1</th>
<th>3</th>
<th>4</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>44</td>
<td>91</td>
<td>61</td>
<td>94</td>
</tr>
</tbody>
</table>

dfs_status:
<table>
<thead>
<tr>
<th>deceased_or_recurrence</th>
<th>living_norecurrence</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>176</td>
</tr>
<tr>
<td></td>
<td></td>
<td>64</td>
</tr>
</tbody>
</table>

days_to_recurrence_or_death:
<table>
<thead>
<tr>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>27.6</td>
<td>668.5</td>
<td>1154.0</td>
<td>1306.0</td>
<td>1785.0</td>
<td>4276.0</td>
<td>64</td>
</tr>
</tbody>
</table>

batch:
<table>
<thead>
<tr>
<th>Length</th>
<th>Class Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>290 character character</td>
</tr>
</tbody>
</table>

drug_treatment:
<table>
<thead>
<tr>
<th>n</th>
<th>y</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>172</td>
<td>117</td>
<td>1</td>
</tr>
</tbody>
</table>

preop_drug_treatment:
<table>
<thead>
<tr>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>290</td>
</tr>
</tbody>
</table>

chemotherapy:
<table>
<thead>
<tr>
<th>n</th>
<th>y</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>172</td>
<td>117</td>
<td>1</td>
</tr>
</tbody>
</table>
Description

The current multistep carcinogenesis models of colon cancer do not fully capture the genetic heterogeneity of the disease, which is additionally complicated by the presence of passenger and driver genetic alterations. The aim of this study was to select in the context of this significant heterogeneity additional genes functionally related to colon cancer development. High-throughput copy number and gene expression data of 36 microsatellite stable sporadic colon cancers resected from patients of a single institution characterized for mutations in APC, KRAS, TP53 and loss of 18q were analyzed. Genes whose expression correlated with the underlying copy number pattern were selected, and their association with the above listed mutations and overall survival was evaluated. Gain of 20q was strongly associated with TP53 mutation, and overall survival with alterations on 7p, 8p, 13q, 18q, and 20q. An association with 18q loss and gain of 8q24 was also observed. New candidate genes with a potential role in colon cancer are PLCG1 on 20q, DBC1 on 8q21, and NDGR1 on 8p24. In addition, an unexpected pattern of loss and mutability was found in the region upstream of the KRAS gene. By integrating copy number alterations with gene expression and mutations in colon cancer associated genes, we have developed a strategy that identifies previously known molecular features and additional players in the molecular landscape of colon cancer.

Copyright 2009 Wiley-Liss, Inc.

Usage
data(GSE16125.GPL5175_eset)

Format
experimentData(eset):
Experiment data
Experimenter name: Reid JF, Gariboldi M, Sokolova V, Capobianco P et al.??Integrative approach for prioritizing cancer genes in sporadic colon cancer.
Laboratory: Reid, Pierotti 2009
Contact information:
Title: Integrative approach for prioritizing cancer genes in sporadic colon cancer.
URL:
PMIDs: 19672874

Abstract: A 225 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HuEx-1.0-st] Affymetrix Human Exon 1.0 ST Array [transcript (gene) version]
platform_shorttitle:
Affymetrix HuEx-1.0-st
platform_summary: huex.1.0.st.v2
platform_manufacturer: Affymetrix
platform_distribution: commercial
platform_accession: GPL5175
platform_technology: in situ oligonucleotide
warnings: No warnings yet

Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1CF A2ML1 ... ZYX (10015 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 10015 features, 36 samples
Platform type: huex.1.0.st.v2
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)

4 observations deleted due to missingness
records n.max n.start events median 0.95LCL 0.95UCL
32.00 32.00 32.00 10.00 6.16 5.26 NA

---------------------------
Available sample meta-data:
---------------------------

alt_sample_name:
Length Class Mode
36 character character

sample_type:
tumor
36

summarystage:
early late NA's
1 27 8

M:
0 1 NA's
14 19 3
### Dstage:
- B: 5
- C: 8
- D: 19
- NA's: 4

### age_at_initial_pathologic_diagnosis:
- Min: 19.00
- 1st Qu: 61.75
- Median: 67.50
- Mean: 65.58
- 3rd Qu: 71.25
- Max: 90.00

### days_to_death:
- Min: 30.0
- 1st Qu: 202.5
- Median: 390.0
- Mean: 926.2
- 3rd Qu: 1658.0
- Max: 2970.0
- NA's: 4

### vital_status:
- deceased: 10
- living: 22
- NA's: 4

### family_history:
- n: 36

### msi:
- MSS: 36

### gender:
- f: 20
- m: 16

### kras:
- mutant: 20
- wt: 16

### tumor_size:
- Min: 2.500
- 1st Qu: 4.000
- Median: 4.000
- Mean: 4.906
- 3rd Qu: 5.000
- Max: 14.000
- NA's: 4

### mutation_apc:
- n: 8
- y: 28

### stageall:
- 1: 1
- 2: 2
- 3: 5
- 4: 19
- NA's: 3

### batch:
- Length: 36
- Class: character
- Mode: character

### preop_drug_treatment:
- n: 36
Staging inadequately predicts metastatic risk in patients with colon cancer. We used a gene expression profile derived from invasive, murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify patients with colon cancer at risk of recurrence. This phase 1, exploratory biomarker study used 55 patients with colorectal cancer from Vanderbilt Medical Center (VMC) as the training dataset and 177 patients from the Moffitt Cancer Center as the independent dataset. The metastasis-associated gene expression profile developed from the mouse model was refined with comparative functional genomics in the VMC gene expression profiles to identify a 34-gene classifier associated with high risk of metastasis and death from colon cancer. A metastasis score derived from the biologically based classifier was tested in the Moffitt dataset. A high score was significantly associated with increased risk of metastasis and death from colon cancer across all pathologic stages and specifically in stage II and stage III patients. The metastasis score was shown to independently predict risk of cancer recurrence and death in univariate and multivariate models. For example, among stage III patients, a high score translated to increased relative risk of cancer recurrence (hazard ratio, 4.7; 95% confidence interval, 1.566-14.05). Furthermore, the metastasis score identified patients with stage III disease whose 5-year recurrence-free survival was >88% and for whom adjuvant chemotherapy did not increase survival time. A gene expression profile identified from an experimental model of colon cancer metastasis predicted cancer recurrence and death, independently of conventional measures, in patients with colon cancer. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Usage
data( GSE17536_eset )

Format

experimentData(eset):
  Experiment data
    Laboratory: Smith JJ,??Beauchamp RD 2009
    Contact information:
    Title: Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.
    URL:
    PMIDs: 19914252

  Abstract: A 260 word abstract is available. Use 'abstract' method.
  Information is available on: preprocessing
  notes:
    platform_title:
      [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle: Affymetrix HG-U133Plus2
platform_summary: hgu133plus2
platform_manufacturer: Affymetrix
platform_distribution: commercial
platform_accession: GPL570
platform_technology: in situ oligonucleotide
warnings: No warnings yet

Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 19320 features, 177 samples
Platform type: hgu133plus2
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)

records  n.max n.start events median 0.95LCL 0.95UCL
177.00  177.00  177.00  73.00  11.08  4.86  NA

---------------------------
Available sample meta-data:
---------------------------

alt_sample_name:
Length  Class  Mode
177  character  character

sample_type:
tumor
177

primarysite:
co
177

summarygrade:
high  low
27  150
| G:        | 1  2  3  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>16 134 27</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>summarystage:</th>
<th>early</th>
<th>late</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24</td>
<td>96</td>
<td>57</td>
</tr>
</tbody>
</table>

| N:            | 0  NA's  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>81  96</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>M:</th>
<th>0  1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>138 39</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dstage:</th>
<th>B  C  D NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>57 57 39 24</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>age_at_initial_pathologic_diagnosis:</th>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>26.00</td>
<td>57.00</td>
<td>66.00</td>
<td>65.48</td>
<td>75.00</td>
<td>92.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>days_to_tumor_recurrence:</th>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.0</td>
<td>298.8</td>
<td>858.9</td>
<td>1126.0</td>
<td>1734.0</td>
<td>4276.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>recurrence_status:</th>
<th>norecurrence</th>
<th>recurrence</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>109</td>
<td>36</td>
<td>32</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>days_to_death:</th>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>27.6</td>
<td>683.4</td>
<td>1268.0</td>
<td>1444.0</td>
<td>2035.0</td>
<td>4276.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>vital_status:</th>
<th>deceased</th>
<th>living</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>73</td>
<td>104</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>gender:</th>
<th>f  m</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>81  96</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>stageall:</th>
<th>1  2  3  4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24 57 57 39</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ethnicity:</th>
<th>black  caucasian  hispanic other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9  151 1 16</td>
</tr>
</tbody>
</table>
dfs_status:
deceased_or_recurrence  living_norecurrence  NA's
36  91  50

days_to_recurrence_or_death:
Min.  1st Qu.  Median  Mean  3rd Qu.  Max.  NA's
27.6  751.3  1380.0 1519.0 2122.0 4276.0 50

disease_specific_mortality:
  n   y
122  55

batch:
  Length  Class  Mode
  177  character  character

preop_drug_treatment:
  n
177

uncurated_author_metadata:
  Length  Class  Mode
  177  character  character

Description

Staging inadequately predicts metastatic risk in patients with colon cancer. We used a gene expression profile derived from invasive, murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify patients with colon cancer at risk of recurrence. This phase 1, exploratory biomarker study used 55 patients with colorectal cancer from Vanderbilt Medical Center (VMC) as the training dataset and 177 patients from the Moffitt Cancer Center as the independent dataset. The metastasis-associated gene expression profile developed from the mouse model was refined with comparative functional genomics in the VMC gene expression profiles to identify a 34-gene classifier associated with high risk of metastasis and death from colon cancer. A metastasis score derived from the biologically based classifier was tested in the Moffitt dataset. A high score was significantly associated with increased risk of metastasis and death from colon cancer across all pathologic stages and specifically in stage II and stage III patients. The metastasis score was shown to independently predict risk of cancer recurrence and death in univariate and multivariate models. For example, among stage III patients, a high score translated to increased relative risk of cancer recurrence (hazard ratio, 4.7; 95% confidence interval, 1.566-14.05). Furthermore, the metastasis score identified patients with stage III disease whose 5-year recurrence-free survival was >88% and for whom adjuvant chemotherapy did not increase survival time. A gene expression profile identified from an experimental model of colon cancer metastasis predicted cancer recurrence and death, independently of conventional measures, in patients with colon cancer. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Usage
data(GSE17537_eset)

Format

experimentData(eset):
Experiment data
Experimenter name: Smith JJ, Deane NG, Wu F, Merchant NB et al.
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.
Laboratory: Smith JJ
Contact information:
Title: Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.
URL: PMID: 19914252
Abstract: A 260 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title: [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle: Affymetrix HG-U133Plus2
platform_summary: hg-u133plus2
platform_manufacturer: Affymetrix
platform_distribution: commercial
platform_accession: GPL570
platform_technology: in situ oligonucleotide
warnings: No warnings yet

Preprocessing: frma

featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 19320 features, 55 samples
Platform type: hg-u133plus2
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)

records n.max n.start events median 0.95LCL 0.95UCL
55 55 55 20 NA NA NA
Available sample meta-data:

<table>
<thead>
<tr>
<th>alt_sample_name:</th>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>55 character</td>
<td>character</td>
<td>character</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>sample_type:</th>
<th>tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>primarysite:</th>
<th>co</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>summarygrade:</th>
<th>high</th>
<th>low</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>33</td>
<td>19</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G:</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>32</td>
<td>3</td>
<td>19</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>summarystage:</th>
<th>early</th>
<th>late</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>36</td>
<td>15</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N:</th>
<th>0</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>19</td>
<td>36</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>M:</th>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>38</td>
<td>17</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dstage:</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>19</td>
<td>17</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>age_at_initial_pathologic_diagnosis:</th>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>23.00</td>
<td>54.00</td>
<td>62.00</td>
<td>62.31</td>
<td>72.00</td>
<td>94.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>days_to_tumor_recurrence:</th>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.00</td>
<td>13.81</td>
<td>1243.00</td>
<td>988.10</td>
<td>1694.00</td>
<td>2303.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>recurrence_status:</th>
<th>no recurrence</th>
<th>recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>36</td>
<td>19</td>
</tr>
</tbody>
</table>
days_to_death:
  Min. 1st Qu. Median  Mean  3rd Qu. Max.
  12.82  950.30 1506.00 1357.00 1801.00 3345.00

vital_status:
deceased  living
  20     35

gender:
f  m
  29  26

stageall:
  1  2  3  4
  4 15 19 17

ethnicity:
  black  caucasian  hispanic
    4     50        1

dfs_status:
deceased_or_recurrence  living_norecurrence  NA's
    19    31         5

days_to_recurrence_or_death:
  Min. 1st Qu. Median  Mean  3rd Qu. Max.  NA's
   0.0   29.1  1505.0 1196.0  1782.0 3345.0      5

disease_specific_mortality:
n  y
  40  15

batch:
  Length  Class  Mode
  55 character  character

uncurated_author_metadata:
  Length  Class  Mode
  55 character  character

Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.

Description

Staging inadequately predicts metastatic risk in patients with colon cancer. We used a gene expression profile derived from invasive, murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify patients with colon cancer at risk of recurrence. This
phase I, exploratory biomarker study used 55 patients with colorectal cancer from Vanderbilt Medical Center (VMC) as the training dataset and 177 patients from the Moffitt Cancer Center as the independent dataset. The metastasis-associated gene expression profile developed from the mouse model was refined with comparative functional genomics in the VMC gene expression profiles to identify a 34-gene classifier associated with high risk of metastasis and death from colon cancer. A metastasis score derived from the biologically based classifier was tested in the Moffitt dataset. A high score was significantly associated with increased risk of metastasis and death from colon cancer across all pathologic stages and specifically in stage II and stage III patients. The metastasis score was shown to independently predict risk of cancer recurrence and death in univariate and multivariate models. For example, among stage III patients, a high score translated to increased relative risk of cancer recurrence (hazard ratio, 4.7; 95% confidence interval, 1.566-14.05). Furthermore, the metastasis score identified patients with stage III disease whose 5-year recurrence-free survival was >88% and for whom adjuvant chemotherapy did not increase survival time. A gene expression profile identified from an experimental model of colon cancer metastasis predicted cancer recurrence and death, independently of conventional measures, in patients with colon cancer. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Usage
data( GSE17538.GPL570_eset )

Format
experimentData(eset):
Experiment data
Experimenter name: Smith JJ, Deane NG, Wu F, Merchant NB et al.
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.
Laboratory: Smith JJ, Beauchamp RD 2009
Contact information:
Title: Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.
URL:
PMIDs: 19914252

Abstract: A 260 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
 Affymetrix HG-U133Plus2
platform_summary:
 hgu133plus2
platform_manufacturer:
 Affymetrix
platform_distribution:
 commercial
platform_accession:
 GPL570
platform_technology:
 in situ oligonucleotide
warnings:
 No warnings yet

Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
  featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
  varLabels: probeset gene
  varMetadata: labelDescription

Details

assayData: 19320 features, 232 samples
Platform type: hgu133plus2
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)

<table>
<thead>
<tr>
<th>records</th>
<th>n.max</th>
<th>n.start</th>
<th>events</th>
<th>median</th>
<th>0.95LCL</th>
<th>0.95UCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>232.00</td>
<td>232.00</td>
<td>232.00</td>
<td>93.00</td>
<td>11.08</td>
<td>5.57</td>
<td>NA</td>
</tr>
</tbody>
</table>

Available sample meta-data:

alt_sample_name:
  Length  Class    Mode
  232     character character

sample_type:
tumor
  232

summarygrade:
  high  low  NA's
  30    183   19

G:
  1  2  3 NA's
  17 166 30 19

summarystage:
  early  late  NA's
  28  132   72

N:
  0  NA's
  100 132

M:
  0  1
  176 56

Dstage:
  B  C  D  NA's
  72  76  56  28
age_at_initial_pathologic_diagnosis:
  Min. 1st Qu. Median  Mean  3rd Qu.  Max.
  23.00  56.00  65.50  64.73  74.00  94.00
days_to_tumor_recurrence:
  Min. 1st Qu. Median  Mean  3rd Qu.  Max.
  0.0  216.2  906.8  1093.0  1713.0  4276.0
recurrence_status:
  norecurrence recurrence NA's
  145  55  32
days_to_death:
  Min. 1st Qu. Median  Mean  3rd Qu.  Max.
  12.82  699.70  1402.00  1423.00  1919.00  4276.00
vital_status:
  deceased living
  93  139
gender:
  f  m
  110  122
stageall:
  1 2 3 4
  28 72 76 56
ethnicity:
  black caucasian hispanic other
  13 201 2 16
dfs_status:
  deceased_or_recurrence living_norecurrence NA's
  55 122 55
days_to_recurrence_or_death:
  Min. 1st Qu. Median  Mean  3rd Qu.  Max.  NA's
  0.0  738.6  1473.0  1428.0  1917.0  4276.0  55
disease_specific_mortality:
  n  y
  162 70
batch:
  Length  Class    Mode
  232  character character
uncurated_author_metadata:
  Length  Class    Mode
  232  character character
MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer.

Description

Distant metastasis is the major cause of death in colorectal cancer (CRC) patients. To identify genes influencing the prognosis of patients with CRC, we compared gene expression in primary tumors with and without distant metastasis using an oligonucleotide microarray. We also examined the expression of the candidate gene in 100 CRC patients by quantitative real-time reverse transcription PCR and studied the relationship between its expression and the prognosis of patients with CRC. As a result, we identified MUC12 as a candidate gene involved in metastasis processes by microarray analysis. Quantitative real-time reverse transcription PCR showed that MUC12 expression was significantly lower in cancer tissues than in adjacent normal tissues (p < 0.001). In Stages II and III CRC, patients with low expression showed worse disease-free survival (p = 0.020). Multivariate analysis disclosed that MUC12 expression status was an independent prognostic factor in Stages II and III CRC (relative risk, 8.236; 95% confidence interval, 1.702-39.849 p = 0.009). Our study revealed the prognostic value of MUC12 expression in CRC patients. Moreover, our result suggests MUC12 expression is a possible candidate gene for assessing postoperative adjuvant therapy for CRC patients.

Usage

data(GSE18105_eset)

Format

experimentData(eset):

{  Experiment data
  Experimenter name: Matsuyama T, Ishikawa T, Mogushi K, Yoshida T et al.?
  Laboratory: Matsuyama, Sugihara 2009
  Contact information:
  Title: MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer.
  URL:
  PMID:s: 20162577

  Abstract: A 188 word abstract is available. Use 'abstract' method.
  Information is available on: preprocessing
  notes:
  platform_title:
    [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
  platform_shorttitle:
    Affymetrix HG-U133Plus2
  platform_summary:
    hgu133plus2
  platform_manufacturer:
    Affymetrix
  platform_distribution:
    commercial
  platform_accession:
    GPL570
}
platform_technology:
in situ oligonucleotide

warnings:
No warnings yet

Preprocessing: fmra

featureData(eset):
An object of class 'AnnotatedDataFrame'

featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)

varLabels: probeset gene

varMetadata: labelDescription

Details

assayData: 19320 features, 111 samples
Platform type: hgu133plus2
---------------------------
Available sample meta-data:
---------------------------

alt_sample_name:
Length Class Mode
111 character character

sample_type:
adjacentnormal tumor
17 94

summarystage:
late NA's
44 67

M:
0 1
85 26

recurrence_status:
norecurrence recurrence
93 18

stageall:
4 NA's
26 85

ethnicity:
other
111

batch:
Length Class Mode
111 character character
GSE2109_eset

preop_drug_treatment:
    n
111

uncurated_author_metadata:
    Length Class Mode
    111 character character

---

**Description**


**Usage**

data( GSE2109_eset )

**Format**

experimentData(eset):
Experiment data
Laboratory: expO, IGC 2005
Contact information:
Title: Expression Project for Oncology (expO)
URL:
PMIDs: PMID unknown

Abstract: A 8 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
    [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
    Affymetrix HG-U133Plus2
platform_summary:
    hgu133plus2
platform_manufacturer:
    Affymetrix
platform_distribution:
    commercial
platform_accession:
    GPL570
platform_technology:
    in situ oligonucleotide
warnings:
    No warnings yet
Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 19320 features, 427 samples
Platform type: hgu133plus2

Available sample meta-data:

alt_sample_name:
<table>
<thead>
<tr>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>427</td>
<td>character</td>
<td>character</td>
</tr>
</tbody>
</table>

date

tumor
427

primarysite:
| core | 343 84 |

summarygrade:
<table>
<thead>
<tr>
<th>high</th>
<th>low</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>75</td>
<td>270</td>
<td>82</td>
</tr>
</tbody>
</table>

G:
| 1 2 3 4 | NA's |
| 10 260 71 | 4 82 |

summarystage:
| early | late | NA's |
| 166   | 177  | 84   |

T:
<table>
<thead>
<tr>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>427</td>
<td>character</td>
<td>character</td>
</tr>
</tbody>
</table>

N:
| 0 1 2 X | NA's |
| 187 101 59 | 3 77 |

M:
| 0 1 X | NA's |
| 274 64 9 | 80 |

Dstage:
GSE21510_eset

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
<td>113</td>
<td>105</td>
<td>5</td>
<td>153</td>
</tr>
</tbody>
</table>

age_at_initial_pathologic_diagnosis:

- Min. 1st Qu. Median Mean 3rd Qu. Max.
- 25.00 55.00 65.00 65.68 75.00 95.00

gender:

- f  m  NA's
- 207 219 1

stageall:

- Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
- 0.000 2.000 2.000 2.516 3.000 4.000 90

ethnicity:

- black  caucasian  hispanic  other
- 23 391 1 12

batch:

- Length  Class  Mode
- 427 character  character

uncurated_author_metadata:

- Length  Class  Mode
- 427 character  character

GSE21510_eset  Clinical significance of osteoprotegerin expression in human colorectal cancer.

Description

This study aimed to identify a novel biomarker or a target of treatment for colorectal cancer (CRC). The expression profiles of cancer cells in 104 patients with CRC were examined using laser microdissection and oligonucleotide microarray analysis. Overexpression in CRC cells, especially in patients with distant metastases, was a prerequisite to select candidate genes. The mRNA expression of candidate genes was investigated by quantitative reverse transcriptase PCR (RT-PCR) in 77 patients as a validation study. We analyzed the protein expression and localization of the candidate gene by immunohistochemical study and investigated the relationship between protein expression and clinicopathologic features in 274 CRC patients. Using microarray analysis, we identified 6 candidate genes related to distant metastases in CRC patients. Among these genes, osteoprotegerin (OPG) is known to be associated with aggressiveness in several cancers through inhibition of apoptosis via neutralization of the function of TNF-related apoptosis-inducing ligand. The mRNA expression of OPG in cancer tissues was significantly higher in patients with distant metastases than those without metastases. Overexpression of OPG protein was associated with significantly worse overall survival and relapse-free survival. Moreover, overexpression of the OPG protein was an independent risk factor for CRC recurrence. Overexpression of OPG may be a predictive biomarker of CRC recurrence and a target for treatment of this disease.©2011 AACR.
Usage

data( GSE21510_eset )

Format

experimentData(eset):
Experiment data
Laboratory: Tsukamoto, Sugihara 2010
Contact information:
Title: Clinical significance of osteoprotegerin expression in human colorectal cancer.
URL:
PMIDs: 21270110

Abstract: A 211 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:

platform_title:
  [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
  Affymetrix HG-U133Plus2
platform_summary:
  hgu133plus2
platform_manufacturer:
  Affymetrix
platform_distribution:
  commercial
platform_accession:
  GPL570
platform_technology:
  in situ oligonucleotide
warnings:
  No warnings yet

Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 19320 features, 148 samples
Platform type: hgu133plus2

Available sample meta-data:

alt_sample_name:
  Length    Class    Mode
GSE21815_eset

Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers.

Description

The functional impact of recently discovered long noncoding RNAs (ncRNAs) in human cancer remains to be clarified. One long ncRNA which has attracted attention is the Hox transcript antisense intergenic RNA termed HOTAIR, a long ncRNA expressed from the developmental HOXC locus located on chromosome 12q13.13. In cooperation with Polycomb complex PRC2, the HOTAIR long ncRNA is reported to reprogram chromatin organization and promote breast cancer metastasis. In this study, we examined the status and function of HOTAIR in patients with stage IV colorectal cancer (CRC) who have liver metastases and a poor prognosis. HOTAIR expression levels were higher in cancerous tissues than in corresponding noncancerous tissues and high HOTAIR expression correlated tightly with the presence of liver metastasis. Moreover, patients with high HOTAIR
expression had a relatively poorer prognosis. In a subset of 32 CRC specimens, gene set enrichment analysis using cDNA array data revealed a close correlation between expression of HOTAIR and members of the PRC2 complex (SUZ12, EZH2, and H3K27me3). Our findings suggest that HOTAIR expression is associated with a genome-wide reprogramming of PRC2 function not only in breast cancer but also in CRC, where upregulation of this long ncRNA may be a critical element in metastatic progression.

Usage

data( GSE21815_eset )

Format

experimentData(eset):

Experiment data
Laboratory: Mori M,??Mimori K,??Yokobori T 2010
Contact information:
Title: Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers.
URL:
PMIDs: 21862635

Abstract: A 201 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
  Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Probe Name vers
ion)
platform_shorttitle:
  Agilent G4112F
platform_summary:
  hgug4112a
platform_manufacturer:
  Agilent
platform_distribution:
  commercial
platform_accession:
  GPL6480
platform_technology:
  in situ oligonucleotide
warnings:
  No warnings yet

Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19686 total)
varLabels: probeset gene
varMetadata: labelDescription
Details

assayData: 19686 features, 141 samples
Platform type: hgug4112a

Available sample meta-data:

alt_sample_name:
<table>
<thead>
<tr>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>141</td>
<td>character</td>
<td>character</td>
</tr>
</tbody>
</table>

sample_type:
adjacentnormal  tumor
9 132

summarygrade:
high  low  NA's
1 65 75

G:
<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3  NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
<td>33</td>
<td>1  75</td>
</tr>
</tbody>
</table>

summarystage:
early  late  NA's
53 78 10

T:
<table>
<thead>
<tr>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>141</td>
<td>character</td>
<td>character</td>
</tr>
</tbody>
</table>

N:
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2  X  NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>70</td>
<td>34</td>
<td>27  1  9</td>
</tr>
</tbody>
</table>

M:
<table>
<thead>
<tr>
<th>0</th>
<th>1  NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>115</td>
<td>17  9</td>
</tr>
</tbody>
</table>

Dstage:
A  B  C  D  NA's
5 59 49 17 11

age_at_initial_pathologic_diagnosis:
<table>
<thead>
<tr>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td>32.00</td>
<td>57.00</td>
<td>65.00</td>
<td>64.73</td>
<td>74.00</td>
<td>85.00</td>
<td>4</td>
</tr>
</tbody>
</table>

gender:
f  m  NA's
59 78 4

stageall:
Description

Colorectal cancer (CRC) is a heterogeneous disease that, on the molecular level, can be characterized by inherent genomic instabilities; chromosome instability and microsatellite instability. In the present study we analyze genome-wide disruption of pre-mRNA splicing, and propose transcriptome instability as a characteristic that is analogous to genomic instability on the transcriptome level. Exon microarray profiles from two independent series including a total of 160 CRCs were investigated for their relative amounts of exon usage differences. Each exon in each sample was assigned an alternative splicing score calculated by the FIRMA algorithm. Amounts of deviating exon usage per sample were derived from exons with extreme splicing scores. There was great heterogeneity within both series in terms of sample-wise amounts of deviating exon usage. This was strongly associated with the expression levels of approximately half of 280 splicing factors (54% and 48% of splicing factors were significantly correlated to deviating exon usage amounts in the two series). Samples with high or low amounts of deviating exon usage, associated with overall transcriptome instability, were almost completely separated into their respective groups by hierarchical clustering analysis of splicing factor expression levels in both sample series. Samples showing a preferential tendency towards deviating exon skipping or inclusion were associated with skewed transcriptome instability. There were significant associations between transcriptome instability and reduced patient survival in both sample series. In the test series, patients with skewed transcriptome instability showed the strongest prognostic association ($P = 0.001$), while a combination of the two characteristics showed the strongest association with poor survival in the validation series ($P = 0.03$). We have described transcriptome instability as a characteristic of CRC. This transcriptome instability has associations with splicing factor expression levels and poor patient survival.

Usage
data( GSE24549.GPL5175.eset )
Format

experimentData(eset):
Experiment data
Experimenter name: Sveen A, esen TH, Rognum TO, Lothe RA, Skotheim RI. Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Med 2011 May 27
Laboratory: Sveen A, esen TH, Rognum TO, Lothe RA, Skotheim RI 2011
Contact information:
Title: Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival.
URL: 
PMIDs: 21619627

Abstract: A 282 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:

[HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [transcript (gene) version]

platform_shorttitle:
Affymetrix HuEx-1_0-st
platform_summary:

huex.1.0.st.v2
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL5175
platform_technology:
in situ oligonucleotide
warnings:
No warnings yet

Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1CF A2ML1 ... ZYX (10015 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 10015 features, 83 samples
Platform type: huex.1.0.st.v2

Available sample meta-data:

alt_sample_name:

Length Class Mode
83 character character

category:

Sample_types
<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>tumor</td>
<td>83</td>
</tr>
<tr>
<td>summarystage: late NA's</td>
<td>37 46</td>
</tr>
<tr>
<td>M:</td>
<td>0 83</td>
</tr>
<tr>
<td>Dstage:</td>
<td>B C 46 37</td>
</tr>
<tr>
<td>msi:</td>
<td>MSI MSS NA's 7 75 1</td>
</tr>
<tr>
<td>stageall:</td>
<td>2 3 46 37</td>
</tr>
<tr>
<td>dfs_status: deceased_or_recurrence</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>living_norecurrence</td>
</tr>
<tr>
<td>days_to_recurrence_or_death:</td>
<td>Min. 1st Qu. Median Mean 3rd Qu. Max. 120.4 441.6 2394.0 2113.0 3650.0 3650.0</td>
</tr>
<tr>
<td>batch:</td>
<td>Length Class Mode 83 character character</td>
</tr>
<tr>
<td>drug_treatment: n</td>
<td>83</td>
</tr>
<tr>
<td>preop_drug_treatment: n</td>
<td>83</td>
</tr>
<tr>
<td>chemotherapy: n y</td>
<td>46 37</td>
</tr>
<tr>
<td>uncurated_author_metadata:</td>
<td>Length Class Mode 83 character character</td>
</tr>
</tbody>
</table>
Colorectal cancer (CRC) is a heterogeneous disease that, on the molecular level, can be characterized by inherent genomic instabilities; chromosome instability and microsatellite instability. In the present study we analyze genome-wide disruption of pre-mRNA splicing, and propose transcriptome instability as a characteristic that is analogous to genomic instability on the transcriptome level. Exon microarray profiles from two independent series including a total of 160 CRCs were investigated for their relative amounts of exon usage differences. Each exon in each sample was assigned an alternative splicing score calculated by the FIRMA algorithm. Amounts of deviating exon usage per sample were derived from exons with extreme splicing scores. There was great heterogeneity within both series in terms of sample-wise amounts of deviating exon usage. This was strongly associated with the expression levels of approximately half of 280 splicing factors (54% and 48% of splicing factors were significantly correlated to deviating exon usage amounts in the two series). Samples with high or low amounts of deviating exon usage, associated with overall transcriptome instability, were almost completely separated into their respective groups by hierarchical clustering analysis of splicing factor expression levels in both sample series. Samples showing a preferential tendency towards deviating exon skipping or inclusion were associated with skewed transcriptome instability. There were significant associations between transcriptome instability and reduced patient survival in both sample series. In the test series, patients with skewed transcriptome instability showed the strongest prognostic association (P = 0.001), while a combination of the two characteristics showed the strongest association with poor survival in the validation series (P = 0.03). We have described transcriptome instability as a characteristic of CRC. This transcriptome instability has associations with splicing factor expression levels and poor patient survival.
Affymetrix HuEx-1.0-st
platform_summary: huex.1.0.st.v2
platform_manufacturer: Affymetrix
platform_distribution: commercial
platform_accession: GPL5175
platform_technology: in situ oligonucleotide
warnings: No warnings yet

Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1CF A2ML1 ... ZYX (10015 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 10015 features, 90 samples
Platform type: huex.1.0.st.v2

Available sample meta-data:

alt_sample_name:
  Length  Class  Mode
  90 character character

data:
sample_type: adjacentnormal tumor
  13  77

summarystage:
  late  NA's
  33  57

M:
  0  NA's
  77  13

Dstage:
  B  C  NA's
  44  33  13

msi:
  MSI  MSS  NA's
  14  51  25
A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes’ B colon cancer patients.

Description

The benefit of postoperative adjuvant chemotherapy in patients with Dukes’ B colorectal cancer is still uncertain and its routine use is not recommended. The five-year relapse rate is approximately 25-40% and the identification of patients at high risk of recurrence would represent an important strategy for the use of adjuvant chemotherapy. We retrospectively analyzed gene expression profiles in frozen tumor specimens from patients with Dukes’ B colorectal cancer by using high density oligonucleotide microarrays. Our results show a subset of 48 genes differentially expressed with an associated probability <0.001 in the t-test. Another statistical procedure based on the Fisher criterion resulted in 11 genes able to separate both groups. We selected the 8 genes present in both subsets. The differential expression of five genes (CHD2, RPS5, ZNF148, BRI3 and MGC23401) in colon cancer progression was confirmed by real-time PCR in an independent set of patients of Dukes’ B and C stages.
Usage

data( GSE2630_eset )

Format

experimentData(eset):

Experiment data
Experimenter name: Bandr??E,??Malumbres R,??Cubedo E,??Sola J,??Garc??Foncillas J,??Labarga A. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes’Var B colon cancer patients. Oncol Rep 2007 May
Laboratory: Bandr??E,??Malumbres R,??Cubedo E,??Sola J,??Garc??Foncillas J,??Labarga A 2005
Contact information:
Title: A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes’Var B colon cancer patients.
URL:
PMIDs: 17390049

Abstract: A 151 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
   platform_title:
      Human 19K oligo array
   platform_shorttitle:
      NA
   platform_summary:
      human 19k oligo array
   platform_manufacturer:
      NA
   platform_distribution:
      non-commercial
   platform_accession:
      GPL2006
   platform_technology:
      spotted oligonucleotide
   warnings:
      No warnings yet

Preprocessing: default
featureData(eset):
   An object of class 'AnnotatedDataFrame'
   featureNames: A1BG-AS1 A1CF ... ZZZ3 (12982 total)
   varLabels: probeset gene
   varMetadata: labelDescription

Details

assayData: 12982 features, 16 samples
Platform type: human 19k oligo array
---------------------------
Available sample meta-data:
---------------------------

alt_sample_name:
   Length   Class   Mode
sample_type:
tumor

primarysite:
co

summarystage:
early

T:
  2 3
  6 10

N:
  0

M:
  0

Dstage:
B

age_at_initial_pathologic_diagnosis:
  Min. 1st Qu. Median  Mean  3rd Qu.  Max.
  42.00  59.50   67.00  64.38  72.00   81.00

recurrence_status:
norecurrence recurrence
  10       6

summarylocation:
  1 r
  12 4

gender:
  f m
  5 11

stageall:
  1 2
  6 10

drug_treatment:
n
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.

Description

Microsatellite instability (MSI) is displayed by approximately 15% of colorectal cancers (CRC). Defective DNA mismatch repair generates mutations at repetitive DNA sequences such as those located in the double strand break (DSB) repair gene MRE11. We assessed the mutational status of MRE11 in a panel of 17 CRC cell lines and 46 primary tumors and found a strong correlation with MSI status in both cell lines and tumors. Therefore, we hypothesized that deficiency in MRE11 may sensitize CRC cells to poly(ADP-ribose) polymerase (PARP-1) inhibition based on the concept of synthetic lethality. We further assessed the activity of the PARP-1 inhibitor, ABT-888, in CRC cell lines and observed preferential cytotoxicity in those MSI cell lines harboring mutations in MRE11 compared with both wild-type cell lines and microsatellite stable (MSS) cell lines. A significant correlation between MRE11 expression levels and cytotoxicity to ABT-888 at 10 μM was observed (R² = 0.915, P < 0.001). Using two experimental approaches, including short hairpin RNA knocking down MRE11 in the wild-type and MSS cell line SW-480 and a second cell line model transfected with mutant MRE11, we experimentally tried to confirm the role of MRE11 in conferring sensitivity to PARP-1 inhibition. Both models led to changes in proliferation in response to ABT-888 at different concentrations, and a drug-response effect was not observed, suggesting a possible contribution of additional genes. We conclude that MSI colorectal tumors deficient in DSB repair secondary to mutation in MRE11 show a higher sensitivity to PARP-1 inhibition. Further clinical investigation of PARP-1 inhibitors is warranted in MSI CRCs.

Usage

data( GSE26682.GPL570_eset )
experimentData(eset):
Experiment data
Contact information:
Title: MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011 Apr 1
URL:
PMIDs: 21300766

Abstract: A 257 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
  [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
  Affymetrix HG-U133Plus2
platform_summary:
  hgu133plus2
platform_manufacturer:
  Affymetrix
platform_distribution:
  commercial
platform_accession:
  GPL570
platform_technology:
  in situ oligonucleotide
warnings:
  No warnings yet

Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1CF A2M ... ZZZ3 (11838 total)
varLabels: probeset gene
varMetadata: labelDescription

Details
assayData: 11838 features, 156 samples
Platform type: hgu133plus2

alt_sample_name:
Length Class Mode
156 character character

sample_type:
tumor
GSE26682.GPL96_eset

MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.

Description

Microsatellite instability (MSI) is displayed by approximately 15% of colorectal cancers (CRC). Defective DNA mismatch repair generates mutations at repetitive DNA sequences such as those located in the double strand break (DSB) repair gene MRE11. We assessed the mutational status of MRE11 in a panel of 17 CRC cell lines and 46 primary tumors and found a strong correlation with MSI status in both cell lines and tumors. Therefore, we hypothesized that deficiency in MRE11 may sensitize CRC cells to poly(ADP-ribose) polymerase (PARP-1) inhibition based on the concept of synthetic lethality. We further assessed the activity of the PARP-1 inhibitor, ABT-888, in CRC cell lines and observed preferential cytotoxicity in those MSI cell lines harboring mutations in MRE11 compared with both wild-type cell lines and microsatellite stable (MSS) cell lines. A significant correlation between MRE11 expression levels and cytotoxicity to ABT-888 at 10 ?M was observed (R² = 0.915, P < 0.001). Using two experimental approaches, including short hairpin RNA knocking down MRE11 in the wild-type and MSS cell line SW-480 and a second cell line model transfected with mutant MRE11, we experimentally tried to confirm the role of MRE11 in conferring sensitivity to PARP-1 inhibition. Both models led to changes in proliferation in response to ABT-888 at different concentrations, and a drug-response effect was not observed, suggesting a possible contribution of additional genes. We conclude that MSI colorectal tumors deficient in DSB repair secondary to mutation in MRE11 show a higher sensitivity to PARP-1 inhibition. Further clinical investigation of PARP-1 inhibitors is warranted in MSI CRCs.

Usage

data( GSE26682.GPL96_eset )
Format

experimentData(eset):
Experiment data
Contact information:
Title: MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
URL:
PMIDs: 21300766

Abstract: A 257 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title: [HG-U133A] Affymetrix Human Genome U133A Array
platform_shorttitle: Affymetrix HG-U133A
platform_summary: hgu133a
platform_manufacturer: Affymetrix
platform_distribution: commercial
platform_accession: GPL96
platform_technology: in situ oligonucleotide
warnings: No warnings yet

Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1CF A2M ... ZZZ3 (12986 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 12986 features, 155 samples
Platform type: hgu133a
---------------------------
Available sample meta-data:
---------------------------

alt_sample_name:
  Length  Class  Mode
  155 character character

sample_type:
tumor
age_at_initial_pathologic_diagnosis:

<table>
<thead>
<tr>
<th></th>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>21.00</td>
<td>66.50</td>
<td>75.00</td>
<td>72.61</td>
<td>80.50</td>
<td>94.00</td>
</tr>
</tbody>
</table>

msi:

- MSI 17
- MSS 123
- NA's 15

gender:

- f 69
- m 86

batch:

<table>
<thead>
<tr>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>155</td>
<td>character</td>
<td>character</td>
</tr>
</tbody>
</table>

uncurated_author_metadata:

<table>
<thead>
<tr>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>155</td>
<td>character</td>
<td>character</td>
</tr>
</tbody>
</table>

Description

Colorectal cancer is one of the most common cancers in the world. Histoclinical staging is efficient, but combination with molecular markers may improve the classification of stage II cancers. Several tumor-suppressor genes have been associated with colorectal cancer, and the most frequent allelic losses have been extensively studied for their prognosis effect, but the results remain controversial. In a previous study, we found a possible influence of the chromosome 5 status in the development of liver metastases in stage II colon cancers. We have here investigated the role of the APC gene, located in chromosome arm 5q, in a series of 183 colon adenocarcinomas through a combined analysis of gene expression, mutation, allelic loss and promoter methylation, and metastasis occurrence. Point mutations were found in 73% of cases and allelic losses were found in 39%; 59% of tumors presented with a biallelic inactivation, with a very strong interdependence of the two APC hits (P = 2.1 x 10(-9)). No association was found between expression, number and type of APC alterations, and metastatic evolution. Our results show that the determination of APC status cannot help in the prediction of metastasis and cannot be used to subclassify stage II colon cancers.

Usage

data( GSE26906_eset )

Format

experimentData(eset):
Experiment data
Experimenter name: Birnbaum DJ, LaiBe S, Ferrari A, Lagarde A et al.
Expression Profiles in Stage II Colon Cancer According to APC Gene Status.

Laboratory: Olschwang S 2011
Contact information:
Title: Expression Profiles in Stage II Colon Cancer According to APC Gene Status.
URL:
PMIDs: 22496922

Abstract: A 199 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:

platform_title: [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle: Affymetrix HG-U133Plus2
platform_summary: hgu133plus2
platform_manufacturer: Affymetrix
platform_distribution: commercial
platform_accession: GPL570
platform_technology: in situ oligonucleotide
warnings: No warnings yet

Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 19320 features, 90 samples
Platform type: hgu133plus2

Available sample meta-data:

alt_sample_name:
  Length Class Mode
  90 character character

sample_type:
tumor
  90

primarysite:
col
GSE26906_eset

90

N: 0 90

M: 0 90

Dstage: 0 90

age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
31.00 58.50 69.50 66.52 75.00 94.00

recurrence_status:
norecurrence recurrence
69 21

msi:
MSS 90

summarylocation:
1 r
65 25

gender:
 f m
47 43

mutation_apc:
n y
22 68

stageall:
2
90

batch:
Length Class Mode
90 character character

drug_treatment:
n 90

preop_drug_treatment:
n
chemotherapy: n

uncurated_author_metadata:

<table>
<thead>
<tr>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>90</td>
<td>character</td>
<td>character</td>
</tr>
</tbody>
</table>

---

**GSE27544_eset**

*Genome-wide profiling characterizes CRCs with genetic instability and specific routes to HLA class I loss and immunoevasce*

**Description**

Bernal M, García F, Concha A, Blanco A, Garrido F, Ruiz-Cabello F

**Usage**

data( GSE27544_eset )

**Format**

experimentData(eset):

Experiment data

Experimenter name: Bernal M, García F, Concha A, Blanco A, Garrido F, Ruiz-Cabello F


Contact information:

Title: Genome-wide profiling characterizes CRCs with genetic instability and specific routes to HLA class I loss and immunoevasce

URL: PMID unknown

Abstract: A 7 word abstract is available. Use 'abstract' method.

Information is available on: preprocessing

notes:

platform_title: [HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate

platform_shorttitle: Affymetrix HT HG-U133+ PM

platform_summary: hthgu133pluspm

platform_manufacturer: Affymetrix

platform_distribution: commercial

platform_accession: GPL13158

platform_technology: in situ oligonucleotide
Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
  featureNames: A1BG A1CF ... ZZZ3 (20741 total)
  varLabels: probeset gene
  varMetadata: labelDescription

Details

assayData: 20741 features, 22 samples
Platform type: hthgu133pluspm

Available sample meta-data:

alt_sample_name:
  Length  Class  Mode
  22      character  character

sample_type:
tumor
  22

msi:
MSI  MSS
  8  14

batch:
2009-10-07
  22

uncurated_author_metadata:
  Length  Class  Mode
  22      character  character

---

GSE28702_eset  Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.

Description

Molecular characterisation using gene-expression profiling will undoubtedly improve the prediction of treatment responses, and ultimately, the clinical outcome of cancer patients. To establish the procedures to identify responders to FOLFOX therapy, 83 colorectal cancer (CRC) patients including 42 responders and 41 non-responders were divided into training (54 patients) and test (29 patients) sets. Using Random Forests (RF) algorithm in the training set, predictor genes for FOLFOX therapy
were identified, which were applied to test samples and sensitivity, specificity, and out-of-bag classification accuracy were calculated. In the training set, 22 of 27 responders (81.4% sensitivity) and 23 of 27 non-responders (85.1% specificity) were correctly classified. To improve the prediction model, we removed the outliers determined by RF, and the model could correctly classify 21 of 23 responders (91.3%) and 22 of 23 non-responders (95.6%) in the training set, and 80.0% sensitivity and 92.8% specificity, with an accuracy of 69.2% in 29 independent test samples. Random Forests on gene-expression data for CRC patients was effectively able to stratify responders to FOLFOX therapy with high accuracy, and use of pharmacogenomics in anticancer therapy is the first step in planning personalised therapy.

Usage

data( GSE28702_eset )

Format

experimentData(eset):
  Experiment data
  Contact information:
  Title: Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.
  URL:
  PMIDs: 22095227

  Abstract: A 185 word abstract is available. Use 'abstract' method.
  Information is available on: preprocessing
  notes:

platform_title:
  [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
  Affymetrix HG-U133Plus2
platform_summary:
  hgu133plus2
platform_manufacturer:
  Affymetrix
platform_distribution:
  commercial
platform_accession:
  GPL570
platform_technology:
  in situ oligonucleotide
warnings:
  No warnings yet

Preprocessing: frma
featureData(eset):
  An object of class 'AnnotatedDataFrame'
  featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
  varLabels: probeset gene
  varMetadata: labelDescription
Details

assayData: 19320 features, 83 samples
Platform type: hgu133plus2

Available sample meta-data:

alt_sample_name:
   Length   Class   Mode
          83 character character

sample_type:
   metastatic tumor
          27      56

primarysite:
   core NA's
          33   23   27

summarygrade:
   high low
          5   78

G:
   1  2  3
   62 16  5

age_at_initial_pathologic_diagnosis:
   Min. 1st Qu. Median   Mean 3rd Qu.   Max.
   31.00  55.00  65.00   62.96  71.00   84.00

location:
   Length   Class   Mode
          83 character character

summarylocation:
   l r NA's
          41  15   27

gender:
   f m
          29  54

drug_name:
   mfolfox6
          83

drug_treatment:
   y
          83

drug_response:
Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa.

Description

The causative molecular pathways underlying the pathogenesis of colorectal cancer (CRC) need to be better characterized. The purpose of our study was to better understand the genetic mechanism of oncogenesis for human colorectal cancer and to identify new potential tumor markers of use in clinical practice. We used cDNA microarrays to compare gene expression profiles of colorectal biopsies from 25 CRC patients and 13 normal mucosa from adjacent non-cancerous tissues. Findings were validated by real-time PCR; in addition, western blotting and immunochemistry analysis were carried out as further confirmation of differential expression at a protein level. Comparing cancerous tissues with normal colonic mucosa we identified 584 known genes differentially expressed to a significant degree (p<0.001). Many of the transcripts that were more abundant in tumors than in non-neoplastic tissues appear to reflect important events for colon carcinogenesis. For example, a significant number of these genes serve as apoptotic inhibitors (e.g. BFAR, BIRC1, BIRC6). Furthermore, we observed the simultaneous up-regulation of HLA-E and the down-regulation of beta2-microglobulin; these genes strongly support a potential tumor escape strategy from immune surveillance in colon cancer tissues. Our study provides new gene candidates in the pathogenesis of human CRC disease. From our results we hypothesize that CRC cells escape immune surveillance through a specific gene expression alteration; moreover, over-expression of several survival genes seems to confer a more anti-apoptotic phenotype. These genes are involved in pathways not previously implicated in CRC pathogenesis and they may provide new targets for therapy.
Usage

data( GSE3294_eset )

Format

experimentData(eset):
Experiment data
Experimenter name: Bianchini M, Levy E, Zucchini C, Pinski V et al.
Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues
Laboratory: Bianchini 2005
Contact information:
Title: Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues
URL:
PMIDs: 16773188

Abstract: A 245 word abstract is available. Use 'abstract' method.

Information is available on: preprocessing

notes:
platform_title:
  UHN SS-Human 19Kv7
platform_shorttitle:
  UHN SS-Human 19Kv7
platform_summary:
  uhn ss-human 19kv7
platform_manufacturer:
  UHN
platform_distribution:
  commercial
platform_accession:
  GPL2829
platform_technology:
  spotted DNA/cDNA
warnings:
  No warnings yet

Preprocessing: default

featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: AA001103 AA001104 ... Z45302 (15437 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 15437 features, 24 samples
Platform type: uhn ss-human 19kv7

Available sample meta-data:

alt_sample_name:
  Length  Class     Mode
sample_type: tumor

primarysite: core re

summarygrade: high low

G:
1 2 3
10 11 3

summarystage: early
24

T:
1 2 3
3 1 20

N:
0 1 2
10 9 5

M:
0
24

Dstage:
B C
6 18

age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
35.00 67.25 76.50 71.46 78.75 89.00

summarylocation:
1 r
12 12

gender:
f m
8 16

stageall:
1 2 3
Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer.

Description

High expression of cancer stem cell (CSC) marker CD133 has been used as a predictor for prognosis in colorectal cancer (CRC), suggesting that enumeration of CSCs, using CD133, is predictive for disease progression. However, we showed recently that both CD133 mRNA and protein are not downregulated during differentiation of colon CSCs, pointing to an alternative reason for the prognostic value of CD133. We therefore set out to delineate the relation between CD133 expression and prognosis. A CRC patient series was studied for expression of CD133 and other CSC markers by microarray and quantitative PCR analysis. In addition, several common mutations were analyzed to determine the relation with CD133 expression. CD133 mRNA expression predicted relapse-free survival in our patient series, whereas several other CSC markers could not. Moreover, no correlation was found between expression of other CSC markers and CD133. Interestingly, high CD133 expression was related to mutations in K-Ras and B-Raf, and inhibition of mutant K-Ras or downstream mitogen-activated protein kinase kinase (MEK) signaling decreases CD133 expression. In addition, an activated K-Ras gene expression signature could predict CD133 expression in our patient set as well as data sets of other tumor types. CD133 expression is upregulated in CRC tumors that have a hyperactivated Ras-Raf-MEK-ERK pathway and is therefore related to mutations in K-Ras or B-Raf. As mutations in either gene have been related to poor prognosis, we conclude that CD133 expression is not indicative for CSC numbers but rather related to the mutation or activity status of the Ras-Raf pathway.

Usage

data(GSE33113_eset)

Format

experimentData(eset):
Experiment data
Laboratory: Medema JP,??Tanis PJ 2011
Contact information:
Title: Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer.
URL:
PMIDs: 22496204
Abstract: A 247 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

platform_shorttitle: Affymetrix HG-U133Plus2
platform_summary: hgu133plus2
platform_manufacturer: Affymetrix
platform_distribution: commercial
platform_accession: GPL570
platform_technology: in situ oligonucleotide
warnings: No warnings yet

Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 19320 features, 96 samples
Platform type: hgu133plus2

Available sample meta-data:

<table>
<thead>
<tr>
<th>alt_sample_name</th>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>96</td>
<td>character</td>
<td>character</td>
</tr>
</tbody>
</table>

sample_type:
adjacentnormal     tumor
|
| 6                        | 90                |

N:
| 0 NA's                |
| 90 6                  |

M:
| 0 NA's                |
| 90 6                  |

Dstage:
B NA's
|
| 90 6                  |

age_at_initial_pathologic_diagnosis:
Colon cancer (CC) pathological staging fails to accurately predict recurrence, and to date, no gene expression signature has proven reliable for prognosis stratification in clinical practice, perhaps because CC is a heterogeneous disease. The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses. Fresh-frozen primary tumor samples from a large multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers were characterized for common DNA alterations, including BRAF, KRAS, and TP53 mutations, CpG island methylator phenotype, mismatch repair status, and chromosomal instability status, and were screened with whole genome and transcriptome arrays. 566 samples fulfilled RNA quality requirements. Unsupervised consensus hierarchical clustering applied to gene expression data from a discovery subset of 443 CC samples identified six molecular subtypes. These subtypes were associated with distinct clinicopathological characteristics, molecular alterations, specific enrichments of supervised gene expression signatures (stem cell phenotype-like, normal-like, serrated CC phenotype-like), and deregulated signaling pathways. Based on their main biological characteristics, we distinguished a deficient mismatch repair subtype, a KRAS mutant subtype, a cancer stem cell subtype, and three chromosomal instability subtypes, including one associated with down-regulated immune pathways, one with up-regulation of the Wnt pathway, and one displaying a normal-like gene expression profile. The classification was validated in the remaining 123 samples plus an independent set of 1,058 CC samples, including eight public datasets. Furthermore, prognosis was analyzed in the subset of stage II-III CC samples. The subtypes C4 and C6, but not the subtypes C1, C2, C3, and C5, were independently associated with shorter relapse-free survival, even after adjusting for age, sex, stage, and the emerging
GSE39582 eset

prognostic classifier Oncotype DX Colon Cancer Assay recurrence score (hazard ratio 1.5, 95% CI 1.1-2.1, p=0.0097). However, a limitation of this study is that information on tumor grade and number of nodes examined was not available. We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA markers. The biological relevance of these subtypes is illustrated by significant differences in prognosis. This analysis provides possibilities for improving prognostic models and therapeutic strategies. In conclusion, we report a new classification of CC into six molecular subtypes that arise through distinct biological pathways.

Usage

data( GSE39582_eset )

Format

experimentData(eset):
Experiment data
Laboratory: Marisa, Boige 2012
Contact information:
Title: Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
URL:
PMIDs: 23700391

Abstract: A 384 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
  [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
  Affymetrix HG-U133Plus2
platform_summary:
  hgu133plus2
platform_manufacturer:
  Affymetrix
platform_distribution:
  commercial
platform_accession:
  GPL570
platform_technology:
  in situ oligonucleotide
warnings:
  No warnings yet

Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
varLabels: probeset gene
varMetadata: labelDescription
Details

assayData: 19320 features, 566 samples
Platform type: hgu133plus2

Available sample meta-data:

<table>
<thead>
<tr>
<th>alt_sample_name:</th>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>566</td>
<td>character</td>
<td>character</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>sample_type:</th>
<th>tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>566</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>primarysite:</th>
<th>co</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>566</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>summarystage:</th>
<th>early</th>
<th>late</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>37</td>
<td>265</td>
<td>264</td>
</tr>
</tbody>
</table>

| N: | 0 NA's | 301 265 |
| M: | 0 1 | 506 60 |

<table>
<thead>
<tr>
<th>Dstage:</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>264</td>
<td>205</td>
<td>60</td>
<td>37</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>age_at_initial_pathologic_diagnosis:</th>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>22.0</td>
<td>59.0</td>
<td>68.0</td>
<td>66.9</td>
<td>76.0</td>
<td>97.0</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>msi:</th>
<th>MSI</th>
<th>MSS</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>75</td>
<td>444</td>
<td>47</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>location:</th>
<th>distal</th>
<th>proximal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>342</td>
<td>224</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>summarylocation:</th>
<th>l</th>
<th>r</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>342</td>
<td>224</td>
</tr>
</tbody>
</table>

| gender: |
### Description

The molecular mechanisms underlying innate tumor drug resistance, a major obstacle to successful cancer therapy, remain poorly understood. In colorectal cancer (CRC), molecular studies have
focused on drug-selected tumor cell lines or individual candidate genes using samples derived from patients already treated with drugs, so that very little data are available prior to drug treatment. Transcriptional profiles of clinical samples collected from CRC patients prior to their exposure to a combined chemotherapy of folinic acid, 5-fluorouracil and irinotecan were established using microarrays. Vigilant experimental design, power simulations and robust statistics were used to restrain the rates of false negative and false positive hybridizations, allowing successful discrimination between drug resistance and sensitivity states with restricted sampling. A list of 679 genes was established that intrinsically differentiates, for the first time prior to drug exposure, subsequently diagnosed chemo-sensitive and resistant patients. Independent biological validation performed through quantitative PCR confirmed the expression pattern on two additional patients. Careful annotation of interconnected functional networks provided a unique representation of the cellular states underlying drug responses. Molecular interaction networks are described that provide a solid foundation on which to anchor working hypotheses about mechanisms underlying in vivo innate tumor drug responses. These broad-spectrum cellular signatures represent a starting point from which by-pass chemotherapy schemes, targeting simultaneously several of the molecular mechanisms involved, may be developed for critical therapeutic intervention in CRC patients. The demonstrated power of this research strategy makes it generally applicable to other physiological and pathological situations.

Usage

data( GSE3964_eset )

Format

experimentData(eset):
Experiment data
Experimenter name: Graudens E, Boulanger V, Mollard C, Mariage-Samson R et al.

Laboratory: Graudens, Imbeaud 2006
Contact information:
Title: Deciphering cellular states of innate tumor drug responses.
URL:
PMIDs: 16542501

Abstract: A 242 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title: 11K_VJF-ARRAY
platform_shorttitle: NA
platform_summary: 11k_vjf-array
platform_manufacturer: Array s/IMAGE - Genexpress
platform_distribution: non-commercial
platform_accession: GPL3282
platform_technology: spotted DNA/cDNA
warnings:
No warnings yet
Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
  featureNames: 384D8-2 38600 ... ZYX (5845 total)
  varLabels: probeset gene
  varMetadata: labelDescription

Details

assayData: 5845 features, 29 samples
Platform type: 11K_vjf-array
---------------------------
Available sample meta-data:
---------------------------

alt_sample_name:
          Length Class Mode
        29 character character

sample_type:
adjacentnormal metastatic tumor
      6   14    9

primarysite:
co
29

summarystage:
late
   29

M:
  1
29

Dstage:
D
 29

age_at_initial_pathologic_diagnosis:
          Min. 1st Qu. Median Mean 3rd Qu. Max.
    48.00  60.00  62.00 61.31  68.00  71.00

summarylocation:
    1
29

gender:
  f  m
 11 18
Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis.
Description

Serrated colorectal carcinomas (CRCs) are morphologically different from conventional CRCs and have been proposed to follow a distinct pathway of CRC formation. Despite studies of single molecular events in this tumor type, the diagnosis of serrated CRC relies on morphology and the putative unique biological character of these tumors has not been established. Here we show that the gene expression profiling of 37 CRCs separated serrated and conventional CRCs into two distinct branches in unsupervised hierarchical clustering (P-value 7.8 x 10(-7)), and revealed 201 differentially expressed genes representing potential biomarkers for serrated CRC. Immunohistochemistry was utilized to verify the key findings in the 37 CRCs examined by expression profiling, and a separate validation set of 37 serrated and 86 conventional CRCs was examined to evaluate the candidate biomarkers in an extended sample material. Ephrin receptor B2, hypoxia-inducible factor 1-alpha and patched appeared as proteins important for genesis of serrated CRC. This study establishes serrated CRCs as a biologically distinct subclass of CRC and represents a step forward in the molecular classification of these cancers. The study also provides a platform to understand the molecular basis of serrated CRC and in long term may contribute to the development of specific treatment options for this tumor type.

Usage

data( GSE4045_eset )

Format

experimentData(eset):
Experiment data
Experimenter name: Laiho P, Kokko A, Vanharanta S, Salovaara R et al.??Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis.??Oncogene2007 Jan 11
Laboratory: Laiho, Aaltonen 2007
Contact information:
Title: Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis.
URL: PMIDs: 16819509

Abstract: A 205 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133A] Affymetrix Human Genome U133A Array
platform_shorttitle:
Affymetrix HG-U133A
platform_summary:
hgU133a
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL96
platform_technology:
in situ oligonucleotide
warnings:
No warnings yet
Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
  featureNames: A1CF A2M ... ZZZ3 (12986 total)
  varLabels: probeset gene
  varMetadata: labelDescription

Details

  assayData: 12986 features, 37 samples
  Platform type: hgu133a
  ---------------------------
  Available sample meta-data:
  ---------------------------

  alt_sample_name:
    Length  Class  Mode
    37 character character

  sample_type:
    tumor
    37

  summarygrade:
    low  NA's
    36  1

  G:
    1  2  3  NA's
    4  28  4  1

  summarystage:
    early  late
    2  35

  M:
    0  1
    35  2

  Dstage:
    B  C  D
    2  33  2

  family_history:
    n  y  NA's
    32  3  2

  msi:
    MSI  MSS
    1  36

  location:
Description

Colorectal cancer patients with lymph node metastases (stage III) show poorer prognosis than those without. Predicting development of recurrence may guide the need for intensive follow-up and/or adjuvant chemotherapy in such patients. The authors’ objective was to identify a set of discriminating genes that could predict recurrence in stage III colorectal cancer. Thirty-six stage III colorectal cancer patients were studied. Tumor samples were obtained from surgically resected specimens. Thirteen patients developed recurrence, whereas 23 patients did not. Gene expression profiles were determined using human HG-U133 Plus 2.0 Gene Chip (Affymetrix, Santa Clara, Calif). The authors identified 45 discriminating genes between patients with and without recurrence. By using this gene set, they established a new model to predict recurrence with an accuracy of 90.9%. The discriminating genes included calcineurin-binding protein 1 (CABIN1), whose expression differed remarkably between patients with and without recurrence (P=.0073). The authors further examined the DNA copy number of CABIN1 and were able to show a significant relation with recurrence (P<.012). Patients having CABIN1 gene loss demonstrated a higher risk of recurrence (odds ratio, 18.8). DNA copy number of CABIN1 alone could predict recurrence with an accuracy of 80.0%. The results of the current study demonstrated that gene expression profiling is useful in predicting recurrence in stage III colorectal cancer. The authors identified CABIN1 among discriminating genes that may play a key role in the development of recurrence. These results may help to establish an individualized therapy for stage III colorectal cancer.

Usage

data( GSE4526_eset )
Format

experimentData(eset):
Experiment data
Experimenter name: Watanabe T, Kobunai T, Sakamoto E, Yamamoto Y et al.??Gene expression signature for recurrence in stage III colorectal cancers.
Laboratory: Watanabe T,??Kobunai T,??Toda E,??Oka T 2006
Contact information:
Title: Gene expression signature for recurrence in stage III colorectal cancers.
URL:
PMIDs: 19016304

Abstract: A 246 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
  [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
  Affymetrix HG-U133Plus2
platform_summary:
  hgu133plus2
platform_manufacturer:
  Affymetrix
platform_distribution:
  commercial
platform_accession:
  GPL570
platform_technology:
  in situ oligonucleotide
warnings:
  No warnings yet

Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 19320 features, 36 samples
Platform: hgu133plus2

Available sample meta-data:

alt_sample_name:
  Length Class Mode
  36 character character

sample_type:
tumor
GSE45270_eset

AMC tubular and serrated adenomas

Description
Profiling project of a panel of tubular adenoma and serrated adenoma patient material collected in the Academic Medical Center

Usage
data( GSE45270_eset )

Format
experimentData(eset):
Experiment data
Experimenter name: Profiling project of a panel of tubular adenoma and serrated adenoma patient material collected in the Academic Medical Center

Laboratory: Medema JP, de Sousa Melo F, Vermeulen L, Jansen M, Dekker E, Van Noesel C, Fessler E

Contact information:
Title: AMC tubular and serrated adenomas
URL:
PMIDs: PMID unknown

Abstract: A 19 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
Affymetrix HG-U133Plus2
platform_summary:
hgu133plus2
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL570
platform_technology:
in situ oligonucleotide
warnings:
No warnings yet

Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (19320 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 19320 features, 13 samples
Platform type: hgu133plus2

Available sample meta-data:

alt_sample_name:

    Length  Class  Mode
    13 character  character

batch:
2012-08-23
13

uncurated_author_metadata:

    Length  Class  Mode
To characterize somatic alterations in colorectal carcinoma, we conducted a genome-scale analysis of 276 samples, analysing exome sequence, DNA copy number, promoter methylation and messenger RNA and microRNA expression. A subset of these samples (97) underwent low-depth-of-coverage whole-genome sequencing. In total, 16% of colorectal carcinomas were found to be hypermutated: three-quarters of these had the expected high microsatellite instability, usually with hypermethylation and MLH1 silencing, and one-quarter had somatic mismatch-repair gene and polymerase ?? (POLE) mutations. Excluding the hypermutated cancers, colon and rectum cancers were found to have considerably similar patterns of genomic alteration. Twenty-four genes were significantly mutated, and in addition to the expected APC, TP53, SMAD4, PIK3CA and KRAS mutations, we found frequent mutations in ARID1A, SOX9 and FAM123B. Recurrent copy-number alterations include potentially drug-targetable amplifications of ERBB2 and newly discovered amplification of IGF2. Recurrent chromosomal translocations include the fusion of NAV2 and WNT pathway member TCF7L1. Integrative analyses suggest new markers for aggressive colorectal carcinoma and an important role for MYC-directed transcriptional activation and repression.
commercial
platform_accession: NA
platform_technology: in situ oligonucleotide
warnings: No warnings yet

Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 15E1.2 2'-PDE ... ZZZ3 (17814 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 17814 features, 130 samples
Platform type: agilent-014850 whole human genome microarray 4x44k g4112f
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)

124 observations deleted due to missingness
records  n.max  n.start  events  median  0.95LCL  0.95UCL
 6.00  6.00  6.00  5.00  1.37  1.16  NA

---------------------------
Available sample meta-data:
---------------------------

unique_patient_ID:
  Length  Class    Mode
  130  character  character

alt_sample_name:
  Length  Class    Mode
  130  character  character

sample_type:
  adjacentnormal   tumor
    7     123

primarysite:
  co  NA's
  129     1

summarystage:
  early  late  NA's
    75    54     1

T:
  1  2  3  4
<table>
<thead>
<tr>
<th>Variable</th>
<th>Min.</th>
<th>1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
</tr>
</thead>
<tbody>
<tr>
<td>age_at_initial_pathologic_diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>days_to_death</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vital_status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>location</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>summarylocation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>kras</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>stageall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>drug_treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
preop_drug_treatment:
  n  y
fu:
  n  NA's
bevacizumab:
  n  NA's
irinotecan:
  n  NA's
cetuximab:
  n  NA's
capcitabine:
  n  NA's
dexamethasone:
  n  NA's
gcsf:
  n  NA's
fudr:
  n  NA's
folfox:
  n  NA's
leucovorin:
  n  NA's
mitomycin:
  n  y  NA's
TCGA.READ_eset

30 1 99

platin:
   n NA's
   31 99

panitumumab:
   n NA's
   31 99

pegfilgrastim:
   n NA's
   31 99

raltitrexed:
   n NA's
   31 99

ancillary:
   n y NA's
   30 1 99

chemotherapy:
   y NA's
   31 99

moltherapy:
   n y NA's
   21 10 99

uncurated_author_metadata:
   Length Class Mode
   130 character character

---

Description

To characterize somatic alterations in colorectal carcinoma, we conducted a genome-scale analysis of 276 samples, analysing exome sequence, DNA copy number, promoter methylation and messenger RNA and microRNA expression. A subset of these samples (97) underwent low-depth-of-coverage whole-genome sequencing. In total, 16% of colorectal carcinomas were found to be hypermutated: three-quarters of these had the expected high microsatellite instability, usually with hypermethylation and MLH1 silencing, and one-quarter had somatic mismatch-repair gene and polymerase ?? (POLE) mutations. Excluding the hypermutated cancers, colon and rectum cancers were found to have considerably similar patterns of genomic alteration. Twenty-four genes were significantly mutated, and in addition to the expected APC, TP53, SMAD4, PIK3CA and KRAS mutations, we found frequent mutations in ARID1A, SOX9 and FAM123B. Recurrent copy-number
alterations include potentially drug-targetable amplifications of ERBB2 and newly discovered amplification of IGF2. Recurrent chromosomal translocations include the fusion of NAV2 and WNT pathway member TCF7L1. Integrative analyses suggest new markers for aggressive colorectal carcinoma and an important role for MYC-directed transcriptional activation and repression.

Usage

data(TCGA.READ_eset)

Format

experimentData(eset):
Experiment data
Laboratory: The Cancer Genome Atlas Network 2012
Contact information:
Title: Comprehensive molecular characterization of human colon and rectal cancer.
URL: 
PMIDs: 22810696

Abstract: A 168 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Agilent 244K Custom Gene Expression G4502A-07-3
platform_shorttitle:
Agilent G4502A-07-3
platform_summary:
agilent-014850 whole human genome microarray 4x44k g4112f
platform_manufacturer:
Agilent
platform_distribution:
commercial
platform_accession:
NA
platform_technology:
in situ oligonucleotide
warnings:
No warnings yet

Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 15E1.2 2'-PDE ... ZZZ3 (17814 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 17814 features, 51 samples
Platform type: agilent-014850 whole human genome microarray 4x44k g4112f
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)

50 observations deleted due to missingness
records  n.max n.start events median 0.95LCL 0.95UCL
1.000  1.000  1.000  1.000  0.866 NA NA

---------------------------
Available sample meta-data:
---------------------------

unique_patient_ID:
  Length Class Mode
  51 character character

alt_sample_name:
  Length Class Mode
  51 character character

sample_type:
tumor  51

primarysite:
  re NA's
  50  1

summarystage:
ear early late
  30  21  1

T:
  1  2  3  4
  3  9 37  2

N:
  0  1  2
 30 11 10

M:
  0  1
 43  8

age_at_initial_pathologic_diagnosis:
  Min. 1st Qu.  Median  Mean 3rd Qu.  Max.
  41.00  62.00  67.00  67.67  73.50  89.00

days_to_tumor_recurrence:
  301  327 NA's
  1  1  49

recurrence_status:
norecurrence recurrence NA's
| Attribute          | Value  \\
|--------------------|--------\
| days_to_death      | 3 2 46 \\
| vital_status       | deceased living NA's \\
| msi                | MSS NA's \\
| location           | rectosigmoid rectum NA's \\
| summarylocation    | 1 NA's \\
| gender             | f m 24 27 \\
| kras               | mutant wt NA's \\
| lymphnodesremoved  | Min. 1st Qu. Median Mean 3rd Qu. Max. 12.00 17.00 22.00 24.73 32.00 65.00 \\
| lymphnodesinvaded  | Min. 1st Qu. Median Mean 3rd Qu. Max. 0.000 0.000 0.000 2.608 3.000 31.000 \\
| stageall           | 1 2 3 4 NA's \\
| ethnicity          | black caucasian NA's \\
| drug_treatment     | y NA's \\
| preop_drug_treatment| n  \\

fu:
    n NA's
    16  35

bevacizumab:
    n NA's
    16  35

irinotecan:
    n NA's
    16  35

cetuximab:
    n NA's
    16  35

capcitabine:
    n NA's
    16  35

dexamethasone:
    n NA's
    16  35

gcsf:
    n NA's
    16  35

fudr:
    n NA's
    16  35

folfiri:
    n NA's
    16  35

folfox:
    n NA's
    16  35

leucovorin:
    n NA's
    16  35

mitomycin:
    n NA's
    16  35

platin:
    n NA's
Description

To characterize somatic alterations in colorectal carcinoma, we conducted a genome-scale analysis of 276 samples, analysing exome sequence, DNA copy number, promoter methylation and messenger RNA and microRNA expression. A subset of these samples (97) underwent low-depth-of-coverage whole-genome sequencing. In total, 16% of colorectal carcinomas were found to be hypermutated: three-quarters of these had the expected high microsatellite instability, usually with hypermethylation and MLH1 silencing, and one-quarter had somatic mismatch-repair gene and polymerase ?? (POLE) mutations. Excluding the hypermutated cancers, colon and rectum cancers were found to have considerably similar patterns of genomic alteration. Twenty-four genes were significantly mutated, and in addition to the expected APC, TP53, SMAD4, PIK3CA and KRAS mutations, we found frequent mutations in ARID1A, SOX9 and FAM123B. Recurrent copy-number alterations include potentially drug-targetable amplifications of ERBB2 and newly discovered amplification of IGF2. Recurrent chromosomal translocations include the fusion of NAV2 and WNT pathway member TCF7L1. Integrative analyses suggest new markers for aggressive colorectal carcinoma and an important role for MYC-directed transcriptional activation and repression.
Usage

data( TCGA.RNASeqV2.READ_eset )

Format

experimentData(eset):
Experiment data
Laboratory: The Cancer Genome Atlas Network 2012
Contact information:
Title: Comprehensive molecular characterization of human colon and rectal cancer.
URL:
PMIDs: 22810696

Abstract: A 168 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
  [RNASeqV2] Illumina HiSeq RNA sequencing
platform_shorttitle:

platform_summary:
  NA
platform_manufacturer:
  Illumina
platform_distribution:
  sequencing
platform_accession:
  NA
platform_technology:
  in situ oligonucleotide
warnings:
  No warnings yet

Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: ? A1BG ... ZZZ3 (20502 total)
varLabels: probeset gene
varMetadata: labelDescription

Details

assayData: 20502 features, 6 samples
Platform type: NA
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)

3 observations deleted due to missingness
records  n.max n.start events median 0.95LCL 0.95UCL
3.00 3.00 3.00 3.00 3.44 2.72 NA
Available sample meta-data:

<table>
<thead>
<tr>
<th>Field</th>
<th>Length</th>
<th>Class</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>unique_patient_ID</td>
<td>6</td>
<td>character</td>
<td>character</td>
</tr>
<tr>
<td>alt_sample_name</td>
<td>6</td>
<td>character</td>
<td>character</td>
</tr>
<tr>
<td>sample_type</td>
<td>tumor</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>primary_site</td>
<td>re</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>summarizestage</td>
<td>early</td>
<td>late</td>
<td>3</td>
</tr>
<tr>
<td>T</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>M</td>
<td>0</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>age_at_initial_pathologic_diagnosis</td>
<td>56 57 72 73 77</td>
<td>1 1 1 1 2</td>
<td></td>
</tr>
<tr>
<td>days_to_tumor_recurrence</td>
<td>630 3316 NA's</td>
<td>1 1 4</td>
<td></td>
</tr>
<tr>
<td>recurrence_status</td>
<td>norecurrence recurrence NA's</td>
<td>3 2 1</td>
<td></td>
</tr>
<tr>
<td>days_to_death</td>
<td>991 1257 1741 NA's</td>
<td>1 1 1 3</td>
<td></td>
</tr>
</tbody>
</table>
vital_status:
deceased  living  NA's
            3   2   1

msi:
MSS  NA's
    5   1

location:
rectosigmoid  rectum
            4   2

summarylocation:
1
6

gender:
f
6

kras:
mutant  wt
       3   3

lymphnodesremoved:
7  14  15  16
1  2  1  2

lymphnodesinvaded:
0  1  5
3  2  1

stageall:
2  3
3  3

ethnicity:
caucasian
       6

preop_drug_treatment:
n
6

uncurated_author_metadata:
    Length  Class  Mode
      6 character  character
Description

To characterize somatic alterations in colorectal carcinoma, we conducted a genome-scale analysis of 276 samples, analysing exome sequence, DNA copy number, promoter methylation and messenger RNA and microRNA expression. A subset of these samples (97) underwent low-depth-of-coverage whole-genome sequencing. In total, 16% of colorectal carcinomas were found to be hypermutated: three-quarters of these had the expected high microsatellite instability, usually with hypermethylation and MLH1 silencing, and one-quarter had somatic mismatch-repair gene and polymerase ?? (POLE) mutations. Excluding the hypermutated cancers, colon and rectum cancers were found to have considerably similar patterns of genomic alteration. Twenty-four genes were significantly mutated, and in addition to the expected APC, TP53, SMAD4, PIK3CA and KRAS mutations, we found frequent mutations in ARID1A, SOX9 and FAM123B. Recurrent copy-number alterations include potentially drug-targetable amplifications of ERBB2 and newly discovered amplification of IGF2. Recurrent chromosomal translocations include the fusion of NAV2 and WNT pathway member TCF7L1. Integrative analyses suggest new markers for aggressive colorectal carcinoma and an important role for MYC-directed transcriptional activation and repression.

Usage

data( TCGA.RNASeqV2_eset )

Format

experimentData(eset):
Experiment data
Laboratory: The Cancer Genome Atlas Network 2012
Contact information:
Title: Comprehensive molecular characterization of human colon and rectal cancer.
URL:
PMIDs: 22810696

Abstract: A 168 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
   [RNASeqV2] Illumina HiSeq RNA sequencing
platform_shorttitle:
platform_summary:
   NA
platform_manufacturer:
   Illumina
platform_distribution:
   sequencing
platform_accession:
   NA
platform_technology:
   in situ oligonucleotide
warnings:
  No warnings yet

Preprocessing: default

featureData(eset):
An object of class 'AnnotatedDataFrame'
  featureNames: ? A1BG ... ZZZ3 (20502 total)
  varLabels: probeset gene
  varMetadata: labelDescription

Details

assayData: 20502 features, 195 samples

Platform type: NA

Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)

174 observations deleted due to missingness

records n.max n.start events median 0.95LCL 0.95UCL
21.000 21.000 21.000 18.000 1.208 0.715 5.605

Available sample meta-data:

unique_patient_ID:
  Length   Class  Mode
  195  character character

alt_sample_name:
  Length   Class  Mode
  195  character character

sample_type:
adjacentnormal  tumor
  14  181

primarysite:
c0
  195

summarystage:
early  late  NA's
  91  103  1

T:
  Length   Class  Mode
  195  character character

N:
  0  1  2  X
 116  51  27  1
<table>
<thead>
<tr>
<th>Variable</th>
<th>Min. 1st Qu.</th>
<th>Median</th>
<th>Mean</th>
<th>3rd Qu.</th>
<th>Max.</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>0</td>
<td>1</td>
<td>X</td>
<td>NA's</td>
<td></td>
</tr>
<tr>
<td>128</td>
<td>29</td>
<td>35</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>age_at_initial_pathologic_diagnosis:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min.</td>
<td>31.00</td>
<td>55.00</td>
<td>66.00</td>
<td>64.95</td>
<td>77.00</td>
</tr>
<tr>
<td>1st Qu.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3rd Qu.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>days_to_tumor_recurrence:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min.</td>
<td>0.0</td>
<td>306.2</td>
<td>458.5</td>
<td>539.7</td>
<td>601.5</td>
</tr>
<tr>
<td>1st Qu.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3rd Qu.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>recurrence_status:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>no recurrence</td>
<td>111</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>recurrence</td>
<td>25</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NA's</td>
<td>59</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>days_to_death:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min.</td>
<td>43.0</td>
<td>187.0</td>
<td>424.0</td>
<td>816.6</td>
<td>1422.0</td>
</tr>
<tr>
<td>1st Qu.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3rd Qu.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vital_status:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>deceased</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>living</td>
<td>119</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NA's</td>
<td>58</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>msi:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSI</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSS</td>
<td>32</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NA's</td>
<td>154</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>location:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length</td>
<td>195</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mode</td>
<td>195</td>
<td>character</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>summarylocation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>l</td>
<td>65</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>r</td>
<td>127</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NA's</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gender:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>f</td>
<td>87</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>m</td>
<td>108</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>kras:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mutant</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>wt</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NA's</td>
<td>182</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>lymphnodesremoved:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min.</td>
<td>0.00</td>
<td>13.25</td>
<td>19.00</td>
<td>23.09</td>
<td>27.00</td>
</tr>
<tr>
<td>1st Qu.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3rd Qu.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>lymphnodesinvaded:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min.</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>1.983</td>
<td>2.000</td>
</tr>
<tr>
<td>1st Qu.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3rd Qu.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>stageall</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>NA's</td>
</tr>
<tr>
<td>----------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>------</td>
</tr>
<tr>
<td></td>
<td>33</td>
<td>73</td>
<td>52</td>
<td>30</td>
<td>7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ethnicity</th>
<th>black</th>
<th>caucasian</th>
<th>other</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>16</td>
<td>152</td>
<td>12</td>
<td>15</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>drug_treatment</th>
<th>n</th>
<th>y</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>21</td>
<td>14</td>
<td>160</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>preop_drug_treatment</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>195</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>fu</th>
<th>n</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60</td>
<td>135</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>bevacizumab</th>
<th>n</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60</td>
<td>135</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>irinotecan</th>
<th>n</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60</td>
<td>135</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>cetuximab</th>
<th>n</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60</td>
<td>135</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>capecitabine</th>
<th>n</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60</td>
<td>135</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>dexamethasone</th>
<th>n</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60</td>
<td>135</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>gcsf</th>
<th>n</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60</td>
<td>135</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>fudr</th>
<th>n</th>
<th>y</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>57</td>
<td>3</td>
<td>135</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>folfiri</th>
<th>n</th>
<th>y</th>
<th>NA's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>59</td>
<td>1</td>
<td>135</td>
</tr>
</tbody>
</table>
folfox:
   n NA's
   60 135

leucovorin:
   n NA's
   60 135

mitomycin:
   n NA's
   60 135

platin:
   n y NA's
   58 2 135

panitumumab:
   n NA's
   60 135

pegfilgrastim:
   n y NA's
   59 1 135

raltitrexed:
   n y NA's
   59 1 135

ancillary:
   n y NA's
   58 2 135

chemotherapy:
   n y NA's
   2 58 135

moltherapy:
   n y NA's
   57 3 135

uncurated_author_metadata:
   Length    Class     Mode
   195 character character
Index

*Topic datasets

- GSE11237_eset, 3
- GSE12225_GPL3676_eset, 5
- GSE12945_eset, 8
- GSE13067_eset, 11
- GSE13294_eset, 13
- GSE14095_eset, 15
- GSE14333_eset, 17
- GSE16125_GPL5175_eset, 20
- GSE17538_GPL570_eset, 29
- GSE17536_eset, 23
- GSE17537_eset, 26
- GSE17538_GPL570_eset, 29
- GSE18105_eset, 33
- GSE2109_eset, 35
- GSE21510_eset, 37
- GSE21815_eset, 39
- GSE24549_GPL5175_eset, 42
- GSE24550_GPL5175_eset, 45
- GSE2630_eset, 47
- GSE26682_GPL570_eset, 50
- GSE26682_GPL96_eset, 52
- GSE26906_eset, 54
- GSE27544_eset, 57
- GSE28702_eset, 58
- GSE3294_eset, 61
- GSE3294_eset, 61
- GSE33113_eset, 64
- GSE39582_eset, 66
- GSE39582_eset, 66
- GSE3964_eset, 69
- GSE4045_eset, 72
- GSE4526_eset, 75
- TCGA_COAD.eset, 83
- TCGA.READ.eset, 83
- curatedCRCData, 2
- curatedCRCData-package, 2
GSE13294_eset, 13
GSE14095_eset, 15
GSE14333_eset, 17
GSE16125.GPL5175_eset, 20
GSE17536_eset, 23
GSE17537_eset, 26
GSE17538.GPL570_eset, 29
GSE18105_eset, 33
GSE2109_eset, 35
GSE21510_eset, 37
GSE21815_eset, 39
GSE24549.GPL5175_eset, 42
GSE24550.GPL5175_eset, 45
GSE2630_eset, 47
GSE26682.GPL570_eset, 50
GSE26682.GPL96_eset, 52
GSE26906_eset, 54
GSE27544_eset, 57
GSE28702_eset, 58
GSE3294_eset, 61
GSE33113_eset, 64
GSE39582_eset, 66
GSE3964_eset, 69
GSE4045_eset, 72
GSE4526_eset, 75
GSE45270_eset, 77
TCGA.COAD_eset, 79
TCGA.READ_eset, 83
TCGA.RNASeqV2.READ_eset, 88
TCGA.RNASeqV2_eset, 91